

# CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption

Justin Harper<sup>1</sup>, Shari Gordon<sup>2,3</sup>, Chi Ngai Chan<sup>4</sup>, Hong Wang<sup>1</sup>, Emily Lindemuth<sup>5</sup>, Cristin Galardi<sup>3,6</sup>, Shane D. Falcinelli<sup>3</sup>, Samuel L. M. Raines<sup>3</sup>, Jenna L. Read<sup>3</sup>, Kevin Nguyen<sup>1</sup>, Colleen S McGary<sup>1</sup>, Michael Nekorchuk<sup>4</sup>, Kathleen Busman-Sahay<sup>4</sup>, James Schawalder<sup>3,6</sup>, Colin King<sup>1</sup>, Maria Pino<sup>1</sup>, Luca Micci<sup>1</sup>, Barbara Cervasi<sup>1</sup>, Sherrie Jean<sup>7</sup>, Andrew Sanderson<sup>8</sup>, Brian Johns<sup>2,3</sup>, A. Alicia Koblansky<sup>3,6</sup>, Heather Amrine-Madsen<sup>3,6</sup>, Jeffrey Lifson<sup>9</sup>, David M. Margolis<sup>3</sup>, Guido Silvestri<sup>1,10</sup>, Katharine J. Bar<sup>5</sup>, David Favre<sup>1,2,3</sup>, Jacob D. Estes<sup>4,11</sup> and Mirko Paiardini<sup>1,10</sup> ✉

**The primary human immunodeficiency virus (HIV) reservoir is composed of resting memory CD4<sup>+</sup> T cells, which often express the immune checkpoint receptors programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), which limit T cell activation via synergistic mechanisms. Using simian immunodeficiency virus (SIV)-infected, long-term antiretroviral therapy (ART)-treated rhesus macaques, we demonstrate that PD-1, CTLA-4 and dual CTLA-4/PD-1 immune checkpoint blockade using monoclonal antibodies is well tolerated, with evidence of bioactivity in blood and lymph nodes. Dual blockade was remarkably more effective than PD-1 blockade alone in enhancing T cell cycling and differentiation, expanding effector-memory T cells and inducing robust viral reactivation in plasma and peripheral blood mononuclear cells. In lymph nodes, dual CTLA-4/PD-1 blockade, but not PD-1 alone, decreased the total and intact SIV-DNA in CD4<sup>+</sup> T cells, and SIV-DNA and SIV-RNA in B cell follicles, a major site of viral persistence during ART. None of the tested interventions enhanced SIV-specific CD8<sup>+</sup> T cell responses during ART or viral control after ART interruption. Thus, despite CTLA-4/PD-1 blockade inducing robust latency reversal and reducing total levels of integrated virus, the degree of reservoir clearance was still insufficient to achieve viral control. These results suggest that immune checkpoint blockade regimens targeting PD-1 and/or CTLA-4, if performed in people living with HIV with sustained aviremia, are unlikely to induce HIV remission in the absence of additional interventions.**

Due to the complexity and diversity of the CD4<sup>+</sup> T cell compartment, identification of the specific subsets that preferentially harbor replication-competent simian immunodeficiency virus/human immunodeficiency virus (SIV/HIV) under long-term antiretroviral therapy (ART) is considered a critical step to facilitate the design of

therapeutics aimed at eliminating persistent viral reservoirs. Recent studies reported high levels of viral DNA in memory CD4<sup>+</sup> T cells expressing immune checkpoint receptors (ICRs)<sup>1–3</sup>, including programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), which define a quiescent population with impaired effector function enforced by distinct, synergistic pathways<sup>4,5</sup>. Lymph node (LN) CD4<sup>+</sup>PD-1<sup>+</sup> T cells, in particular follicular helper T cells (T<sub>FH</sub>) in the B cell follicle (BCF), represent a major potential source of inducible, replication-competent virus in ART-treated, HIV-infected subjects<sup>2,6</sup>. Chronic viral infection enhances PD-1 expression on HIV-specific CD8<sup>+</sup> T cells, which exhibit impaired cytokine production upon antigen stimulation, diminished proliferative capacity, abnormal cellular differentiation and exhaustion<sup>7,8</sup>. In rhesus macaques (RMs) we have demonstrated that, in addition to PD-1<sup>+</sup> T<sub>FH</sub> cells, memory CD4<sup>+</sup>CTLA-4<sup>+</sup>PD-1<sup>+</sup> T cells harbor replication-competent SIV, phenotypically overlap with regulatory T cells (T<sub>REGs</sub>), reside in the lymphoid T cell zone (TCZ) and increase their contribution to the viral reservoir over time with ART<sup>1</sup>. Collectively, these observations provide a strong rationale for targeting CTLA-4/PD-1-expressing T cells with the aim of relieving ('shock') the quiescent transcriptional state that promotes viral latency while also restoring immune effector functions that may result in viral clearance ('kill').

As a proof of concept in ART-treated, HIV-infected patients, the sequential in vivo blockade of CTLA-4<sup>9</sup> and PD-1<sup>10</sup> yielded greatly expanded levels of cell-associated HIV-RNA in a patient with metastatic melanoma; furthermore, PD-1 blockade produced significant declines in HIV-DNA in a patient with relapsed non-small-cell lung cancer<sup>11</sup>, but has proven highly variable<sup>10,12,13</sup>. In viremic, SIV-infected RMs (without ART or with viremia incompletely suppressed by ART), CTLA-4 blockade has produced inconsistent results on viral reactivation and on SIV-specific CD8<sup>+</sup> T cell responses<sup>14,15</sup>. Similarly, PD-1 blockade decreased set-point viremia

<sup>1</sup>Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA. <sup>2</sup>HIV Discovery Performance Unit, GlaxoSmithKline, Research Triangle Park, NC, USA. <sup>3</sup>UNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. <sup>4</sup>Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA. <sup>5</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. <sup>6</sup>HIV Discovery, ViiV Healthcare, Research Triangle Park, NC, USA. <sup>7</sup>Division of Animal Resources, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA. <sup>8</sup>Biopharm Innovation, GlaxoSmithKline, Stevenage, UK. <sup>9</sup>AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. <sup>10</sup>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA. <sup>11</sup>Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.

✉e-mail: [mirko.paiardini@emory.edu](mailto:mirko.paiardini@emory.edu)

and improved SIV-specific T cell responses during chronic infection<sup>16</sup>, with only a modest effect in enhancing antiviral responses during short-term ART<sup>17</sup> and no impact on long-term ART<sup>18</sup>. In this study, we examine the immunologic and virologic effects and the therapeutic potential of PD-1 and CTLA-4 blockade in SIV-infected RMs treated with long-term ART.

## Results

**CTLA-4 and PD-1 blockade is biologically active in SIV-infected, ART-treated RMs.** Thirty-four RMs were intravenously infected with SIVmac<sub>239</sub> (Fig. 1a); RM Rff16 was euthanized at day 25 post-infection (d25 p.i.) related to rapid AIDS progression. Set-point viral loads ranged between  $2.5 \times 10^5$  and  $8.4 \times 10^7$  copies per ml, with one outlier (RKt16 at  $8 \times 10^2$  copies per ml). At d60 p.i. ART consisting of tenofovir (TDF), dolutegravir (DTG) and emtricitabine (FTC) was initiated and maintained for up to 13.5 months. Viremia was controlled to undetectable levels (<60 copies per ml) with transient blips observed in RAI16, ROP16 and RZ116 RMs (Extended Data Figs. 1 and 2a). RMs were stratified into treatment groups based on acute ('peak') and set-point ('chronic' at ART initiation) viral load, duration of virologic suppression, MHC haplotype (6 Mamu-A\*01<sup>+</sup>) and a lack of naturally arising, cross-reactive anti-drug antibodies (ADAs) against the therapeutic immune checkpoint blockade (ICB) monoclonal antibodies (mAb) in plasma (Supplementary Fig. 1 and Supplementary Table 1). Four doses of mAbs targeting PD-1 and/or CTLA-4 were infused weekly. RMs had an average of  $181.4 \pm 4.9$  days of virologic suppression, ensuring that immune interventions and SIV-DNA reservoir measurements were not conducted in the setting of overt viral replication. Two weeks after mAb administrations, all animals underwent ART analytical therapy interruption (ATI) and were followed for seven months.

In non-human primates (NHPs), repeated doses of ipilimumab, a humanized immunoglobulin-G1 (IgG1) anti-CTLA-4 mAb, did not induce ADAs<sup>14,15</sup>; however, nivolumab, a humanized IgG4 anti-PD-1 mAb, was immunogenic with blunted proliferative responses upon serial administration<sup>19</sup>. To improve the effective dosing duration, an IgG4 nivolumab-biosimilar anti-PD-1 was rhesusized with human variable domains and macaque constant regions ( $\alpha$ PD-1,  $n=6$ ) and further formulated as a bispecific IgG1 mAbdAb with ipilimumab-biosimilar anti-CTLA-4 mAb (BsAb,  $n=8$ ). Additional treatment groups include ipilimumab-biosimilar anti-CTLA-4 mAb ( $\alpha$ CTLA-4,  $n=6$ ) with Fc- $\gamma$  binding activity, anti-CTLA-4 mAb in conjunction with an anti-PD-1 mAb (combined blockade,  $n=7$ ) and a control mAbdAb (VHDUM) that lacks known specificity (control,  $n=6$ ; Extended Data Fig. 2b).

Infusion resulted in sustained plasma concentrations of all mAbs through four cycles of administration (Extended Data Fig. 3a), but the BsAb formulation had faster in vivo clearance. Few animals showed the emergence of ADAs, which were associated with a reduction in plasma mAb concentrations (Extended Data Fig. 3b).

Target receptor engagement was remarkably high, both for memory (CD95<sup>+</sup>) CD4<sup>+</sup> and CD8<sup>+</sup> T cells, as confirmed via PD-1 occupancy using the EH12.2H7 detection antibody in peripheral blood mononuclear cells (PBMCs; Fig. 1b–d and Supplementary Fig. 2) and LN biopsies (Fig. 1e–g); however, BsAb treatment was associated with reduced PD-1 occupancy by d21 post-treatment (p.t.), consistent with its pharmacokinetics (Extended Data Fig. 3a). PD-1 occupancy was observed within LN-resident T<sub>HH</sub> cells (PD-1<sup>hi</sup>CXCR5<sup>+</sup>CD95<sup>+</sup>CD4<sup>+</sup> T cells), indicative of follicular distribution, without impacting follicle homing as measured by CXCR5 expression (Fig. 1h, data not shown)<sup>20</sup>. Thus, the tested mAbs engage their cognate receptor in blood and LN, whereas the BsAb fail to improve plasma concentrations or target engagement as compared to combined blockade.

Mono- and dual-ICB were well tolerated without evidence of treatment-induced clinical pathology, acute inflammatory reactions, cytokine release syndrome, abnormal blood counts, nephrotoxicity or hepatotoxicity (Supplementary Table 2 and Supplementary Fig. 3a–c). None of the treatment regimens impacted the number of circulating neutrophils or eosinophils, while  $\alpha$ PD-1 exhibited a transient increase in the number of monocytes (Supplementary Fig. 3d). Immunophenotypic analysis of unoccupied PD-1 epitopes (clone 913429) in LN demonstrated that PD-1 blockade did not result in an expansion or contraction of PD-1<sup>+</sup> T cells (data not shown) or T<sub>HH</sub> (Supplementary Fig. 4a,b). CTLA-4 blockade, particularly in combination with PD-1 blockade, was associated with an expansion of CTLA-4<sup>+</sup> memory CD4<sup>+</sup> T cells in PBMCs and LN (Supplementary Fig. 4c,d), and significantly increased levels of CD4<sup>+</sup> regulatory T cells (T<sub>REG</sub>; CD25<sup>+</sup>CD127<sup>+</sup>FoxP3<sup>+</sup>) in PB and LN (Fig. 1i,j). Furthermore, the magnitude of the CD4<sup>+</sup> T<sub>REG</sub> expansion at day 28 p.t. was directly correlated with the plasma concentration of CTLA-4 blocking mAbs ( $r=0.5692$ ,  $P=0.0434$ ; Supplementary Fig. 4e). Therefore, dual CTLA-4/PD-1 blockade was biologically active and demonstrated an acceptable safety profile in ART-treated, SIV-infected RMs.


**T cell proliferative and effector responses are synergistically improved by dual CTLA-4/PD-1 blockade.** As ICB was biologically active, we determined how those interventions impacted the levels of proliferating T cells. Blockade of CTLA-4, particularly when combined with PD-1 blockade, was remarkably effective in expanding the number of circulating memory CD4<sup>+</sup> T cells expressing Ki-67. Specifically, combined blockade induced a large increase in the number of PB memory CD4<sup>+</sup>Ki-67<sup>+</sup> T cells (from  $106.3 \pm 9.263$  to  $642.6 \pm 80.04$  at d7 p.t.; Fig. 2a,b) and PB memory CD8<sup>+</sup>Ki-67<sup>+</sup> T cells (from  $71.43 \pm 24.66$  to  $212.3 \pm 54.96$  at d14 p.t.; Fig. 2c,d). Increased T cell cycling induced by CTLA-4 blockade alone, and more significantly in combination with PD-1 blockade, was coupled with a marked expansion of circulating effector-memory T cells (T<sub>EM</sub>, CCR7<sup>+</sup>CD95<sup>+</sup>). With a full treatment cycle, the

**Fig. 1 | CTLA-4 and PD-1 blockade is biologically active in SIV-infected, ART-treated RMs.** **a**, Study design. A total of 34 RMs were infected intravenously (i.v.) with 300 median tissue culture infectious dose (TCID<sub>50</sub>) SIVmac<sub>239</sub>. At d60 p.i. ART (FTC/DTG/TDF) was initiated and maintained for up to 13.5 months. RMs were administered weekly i.v. ICB therapy over four weeks, and ART was interrupted two weeks afterwards with a seven-month follow-up. Peripheral blood (PB) and lymph node (LN) biopsies were collected at the specified time points. **b,c,e,f**, The frequency of residual PD-1 expression upon mAb occupancy relative to baseline (d-29 post-treatment (p.t.)) was longitudinally quantified at the masked EH12.2H7 locus in memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells in PBMCs (**b,c**) and LNs (**e,f**). **d,g**, Representative stains are shown for PD-1 occupancy in memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells (as indicated above; 5 of 33 single-replicate stains within each parent per tissue) in PBMCs (**d**) and LN (**g**). **h**, Representative stains are shown for PD-1 occupancy against CXCR5 expression within LN memory CD4<sup>+</sup> T cells over time by ICB treatment (indicated at the right; 6 of 99 single-replicate stains). **i,j**, The number and frequency of CD4<sup>+</sup> T<sub>REG</sub> cells (CD95<sup>+</sup>CD25<sup>+</sup>CD127<sup>+</sup>FoxP3<sup>+</sup>) were quantified in PB (**i**) and LN (**j**), respectively. RMs are color-coded and grouped based on ICB therapy as follows, with population sizes as indicated for all analyses: vehicle/dummy (VHDUM) mAbdAb (controls,  $n=6$ ), black; anti-CTLA-4 mAb ( $\alpha$ CTLA-4,  $n=6$ ), blue; anti-PD-1 mAb ( $\alpha$ PD-1,  $n=6$ ), pink; anti-CTLA-4 plus anti-PD-1 mAb (combined blockade,  $n=7$ ), red; anti-CTLA-4/PD-1 mAbdAb (BsAb,  $n=8$ ), purple. All averaged data are presented as mean  $\pm$  s.e.m. and were analyzed (**b,c,e,f,i,j**) with a two-sided, mixed-effects model with Dunnett's correction for multiple comparisons relative to controls. Color-coded statistical asterisks indicate significance between controls and the treatment group of the respective color. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .


number of  $T_{EM}$  increased from  $111.9 \pm 13.52$  to  $457.0 \pm 66.30$  cells per  $\mu$ l ( $P < 0.0001$ ) for  $CD4^+$  T cells and from  $446.0 \pm 165.5$  to  $781.4 \pm 196.9$  cells per  $\mu$ l for  $CD8^+$  T cells ( $P = 0.0130$ ; Fig. 2e,f) with combined blockade, while those levels remain virtually unchanged in controls or after  $\alpha$ PD-1 monotherapy. Therefore, dual

CTLA-4/PD-1 blockade exhibited strong synergy in enhancing the number of  $T_{EM}$  and proliferative responses in PB.

In lymphoid tissue, CTLA-4 blockade enhanced Ki-67 expression in memory  $CD4^+$  T cells ( $\alpha$ CTLA-4,  $P = 0.0125$ ; BsAb,  $P = 0.0137$ ; combined blockade,  $P < 0.0001$ ; Fig. 2g),  $CD4^+$   $T_{EM}$







**Fig. 2 | T cell proliferative and effector responses are synergistically improved by dual CTLA-4/PD-1 blockade.** **a-d**, The number of cycling (Ki-67<sup>+</sup>) memory CD4<sup>+</sup> (**a**) and CD8<sup>+</sup> (**c**) T cells per  $\mu$ l of PB were measured, and representative longitudinal stains are shown within memory CD4<sup>+</sup> (**b**) and CD8<sup>+</sup> (**d**) T cells segmented by ICB (indicated at the right; RUM16 and 118\_14 are shown as 12 of 198 single-replicate stains within each parental population). **e-i**, The number of CD4<sup>+</sup> (**e**) and CD8<sup>+</sup> (**f**) effector-memory cells (T<sub>EM</sub>; CD95<sup>+</sup>CCR7<sup>+</sup>) per  $\mu$ l of PB were quantified longitudinally as was the frequency of cycling cells in LN memory CD4<sup>+</sup> (**g**), CD4<sup>+</sup> T<sub>EM</sub> (**h**) and memory CD8<sup>+</sup> (**i**) T cells. **j-l**, Following ICB (d28 p.t.), the frequency of immune activation (HLA-DR<sup>+</sup>CD38<sup>+</sup>) was quantified in LN memory CD4<sup>+</sup> (**j**) and memory CD8<sup>+</sup> (**k**) T cells, in addition to the frequency of CXCR3<sup>+</sup> CD4<sup>+</sup> T<sub>FH</sub> (CXCR5<sup>+</sup>PD-1<sup>hi</sup>CD95<sup>+</sup>) (**l**). Individual animals are represented by open circles. All RMs are color-coded and grouped based on ICB therapy as follows, with population sizes as indicated for all analyses: controls ( $n=6$ ), black; αCTLA-4 ( $n=6$ ), blue; αPD-1 ( $n=6$ ), pink; combined blockade ( $n=7$ ), red; BsAb ( $n=8$ ), purple. All averaged data are presented as mean  $\pm$  s.e.m. and were analyzed with a two-sided, mixed-effects model with Dunnett's correction for multiple comparisons relative to controls (**a,c,e,f,i**) or a Mann-Whitney U test (**j-l**). Color-coded statistical asterisks indicate significance between control animals and the treatment group of that color. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .

(Fig. 2h) and memory CD8<sup>+</sup> T cells (BsAb,  $P=0.0235$ ; combined blockade,  $P=0.0009$ ; Fig. 2i). Dual blockade also uniquely increased activation (HLA-DR<sup>+</sup>CD38<sup>+</sup>) of both memory CD4<sup>+</sup> (combined blockade,  $P=0.0082$ ; BsAb,  $P=0.0200$ ; Fig. 2j) and CD8<sup>+</sup> T cells (combined blockade,  $P=0.0221$ ; Fig. 2k). Only dual blockade produced an increase in the frequency of CXCR3<sup>+</sup> T<sub>FH</sub> cells, which produce interferon- $\gamma$  (IFN- $\gamma$ ) and provide B cell help for IgG production (combined blockade,  $P=0.0047$ ; BsAb,  $P=0.0426$ ;

Fig. 2l)<sup>21</sup>. Therefore, combined blockade results in increased T cell activation and cell cycling, suggesting the treatment may enhance viral reactivation and/or viral clearance.

**SIV-specific CD8<sup>+</sup> T cell responses are not improved by blockade of PD-1 and/or CTLA-4 during long-term ART.** Blockade of CTLA-4 and PD-1 signaling is predicted to improve the function of exhausted cytotoxic T lymphocytes (CTL; that is 'kill').



Immunophenotypic analysis revealed that dual blockade increased the frequency of granzyme B expression in LN CTLA-4<sup>+</sup>PD-1<sup>+</sup> and CTLA-4<sup>+</sup>PD-1<sup>-</sup> subsets of memory CD8<sup>+</sup> T cells (Extended Data Fig. 4a,b). Following CellTrace labeling and T cell receptor stimulation, combined blockade leads to a reduction of non-dividing CD4<sup>+</sup> T cells at d21 p.t. ( $P=0.0463$ ), with a less pronounced effect within CD8<sup>+</sup> T cells (Supplementary Fig. 5a–d). Before therapy, SIV-specific memory CD8<sup>+</sup> T cells, as determined via Gag-CM9 tetramer staining, were enriched in PD-1 and eomesodermin (EOMES), a T-box transcription factor that regulates T cell exhaustion<sup>22,23</sup> (Extended Data Fig. 5a,b). ICB failed to substantially expand the frequency of SIV-specific memory CD8<sup>+</sup> T cells in LN and PBMCs (Extended Data Fig. 6a,b) or to significantly enhance markers of activation, proliferation or cytolytic responses (Extended Data Fig. 5c–j). In ELISpot analyses in PBMCs and LN, none of the interventions increased IFN- $\gamma$  production in response to SIV-Gag (Extended Data Fig. 6c,d) or SIV-Env peptide stimulation (Supplementary Fig. 6a,b). Furthermore,  $\alpha$ CTLA-4 monotherapy resulted in a significant fold change reduction in SIV-Gag-stimulated IFN- $\gamma$  responses in PBMCs ( $P=0.0411$ ; Extended Data Fig. 6c) and a cross-sectional decrease in the SIV-Env-stimulated IFN- $\gamma$  response in LN (Supplementary Fig. 6b). Finally, ICB failed to impact the frequency of PB memory T cells co-expressing interleukin-2 (IL-2), IFN- $\gamma$ , tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and/or CD107a following ex vivo SIV-Gag (Extended Data Fig. 6e,f) or SIV-Env peptide stimulation (Supplementary Fig. 6c,d). In SIV-Gag peptide responding T cells, defined as those expressing either IFN- $\gamma$ , IL-2, TNF- $\alpha$  or CD107a, therapies incorporating CTLA-4 blockade significantly increased the frequency of proliferating memory CD4<sup>+</sup> T cells relative to baseline ( $\alpha$ CTLA-4,  $P=0.0109$ ; combined blockade,  $P=0.0068$ ) and combined blockade alone enhanced the proliferation of memory CD8<sup>+</sup> T cells relative to controls ( $P=0.0259$ ) (Supplementary Fig. 6e,f). Overall, these findings indicated that ICB is insufficient to enhance SIV-specific responses when performed in the context of long-term ART suppression.

**CTLA-4 and PD-1 combined blockade induces robust viral reactivation in ART-treated, SIV-infected RMs.** By promoting cell cycling, ICB is proposed to function as a latency-reversing agent (LRA) by increasing viral transcription<sup>24</sup>. Longitudinal quantification of plasma viral loads demonstrated detectable viral RNA on ART in a fraction of RMs across all interventions (Fig. 3a–e). Enhanced viral reactivation was observed for both co-blockades as compared to monotherapies, stratified either by animal or by the number of detectable events (Fig. 3f). In particular, combined blockade enhanced both the frequency (57.1% of RMs and 32.1% of events) and magnitude (average,  $9.1 \times 10^2$  SIV-RNA copies per ml) of detectable plasma SIV-RNA relative to controls (0% of events),  $\alpha$ PD-1 (12.5% of events;  $7.2 \times 10^2$

SIV-RNA copies per ml) and  $\alpha$ CTLA-4 monotherapy (12.5% of events;  $7.1 \times 10^2$  SIV-RNA copies per ml), thus suggesting a synergistic effect of blocking PD-1 and CTLA-4 in reversing viral latency. Furthermore, measurable virus induction after ICB monotherapy skewed toward later treatments, with 66.7% of reactivation events occurring after the third infusion, while both dual blockade strategies produced 66.7% of their reactivation events before the third infusion. As expected based on the early loss of PD-1 occupancy, the BsAb group produced fewer unique reactivation events following the third infusion as compared to combined blockade. The propensity towards viral reactivation was directly associated with the set-point plasma viral load ( $P=0.0038$ ; Fig. 3g and Extended Data Fig. 1), but not with peak viral load or the size of the SIV reservoir during suppressive ART (data not shown). Of note, only combined blockade yielded enhanced levels of cell-associated SIV-RNA in PBMCs following the first (d7 p.t.) and fourth infusion (d28 p.t.) as compared to baseline ( $P=0.0156$ ;  $P=0.0156$ ; Fig. 3h). However, with some heterogeneity between individual animals, dual CTLA-4/PD-1 blockade acts as a synergistic, latency-reversing intervention that induces robust levels of viral reactivation.


**CTLA-4 and dual blockade, but not PD-1 blockade, reduces the total and intact SIV-DNA in LN.** To determine the impact of ICB-induced viral reactivation and effector cell expansion on viral persistence, we longitudinally measured the levels of cell-associated SIV-DNA with qPCR. In PBMCs, ICB did not impact viral DNA content relative to baseline (Extended Data Fig. 7a), but combined blockade increased the transcriptional ratio of SIV-RNA to SIV-DNA relative to baseline ( $P=0.0313$ ;  $P=0.0156$ ; Extended Data Fig. 7b), consistent with induction of viral expression. Mononuclear cells derived from LN, a major site of viral persistence<sup>25</sup>, were sorted for memory CD4<sup>+</sup> T cell subsets: T<sub>EH</sub> (PD-1<sup>+</sup>CD200<sup>hi</sup>), T<sub>REG</sub> (CD25<sup>+</sup>CD127<sup>-</sup>), central-memory (T<sub>CM</sub>, CCR7<sup>+</sup>) and effector-memory (T<sub>EM</sub>, CCR7<sup>-</sup>; Fig. 4a). Importantly, CTLA-4 blockade, whether as mono- or combination therapy, significantly decreased cell-associated SIV-DNA in T<sub>EM</sub> ( $\alpha$ CTLA-4,  $P=0.0031$ ; combined blockade,  $P=0.0044$ ; BsAb,  $P=0.0147$ ; Fig. 4b). The preferential reduction of SIV-DNA within the T<sub>EM</sub> compartment is consistent with the observation that this subset is the most affected in terms of cell cycling by combined blockade (Fig. 2h), perhaps suggesting the depletion of cycling cells in which SIV-RNA production was reactivated.

To assess if therapy-mediated reductions in total SIV-DNA translated into a functional decrease in intact virus, we assayed for integrated viral genomes in LN CD4<sup>+</sup> cells using the intact proviral DNA assay (IPDA)<sup>26</sup>. The intact reservoir was remarkably stable in controls and with anti-PD-1 monotherapy (controls,  $1,458 \pm 475.4$  to  $1,646 \pm 424.5$ ;  $\alpha$ PD-1,  $1,448 \pm 300.6$  to  $1,514 \pm 295.4$  intact proviral

**Fig. 3 | CTLA-4 and PD-1 combined blockade induces robust viral reactivation in ART-treated, SIV-infected RMs.** Single animal viral loads (SIV<sub>mac239</sub> RNA copies per ml of plasma) were quantified during ICB therapy on ART immediately before each infusion and one week following the terminal dose. **a–e**, Viral loads are segmented by treatment: control ( $n=6$ ) (**a**),  $\alpha$ CTLA-4 ( $n=6$ ) (**b**),  $\alpha$ PD-1 ( $n=6$ ) (**c**), combined blockade ( $n=7$ ) (**d**) and BsAb ( $n=8$ ) (**e**). The dotted horizontal line indicates the assay limit of detection ( $\leq 60$  copies per ml), with undetectable events plotted as 30 copies per ml. The x axes are not drawn to scale—single time points have been spread and are grouped between dotted lines (as indicated below). **f**, Treatment-grouped reactivation events ( $>60$  copies per ml) are displayed on a logarithmic scale. Progressive color shading indicates which infusion (number 1, 2, 3 or 4) the event followed (d7, 14, 21 or 28 p.t., respectively), and individual animals are indicated by shape. The frequency and number of reactivation events is given relative to the number of animals and the total number of assayed events per treatment (as indicated above). **g**, The set-point plasma viral load (d52 p.i.) was stratified by subsequent viral reactivation in plasma (positive,  $n=13$ ; negative,  $n=14$ ). **h**, The numbers of log-transformed cell-associated SIV-RNA copies per  $10^6$  cells in bulk PBMCs were quantified by 12 replicate quantitative polymerase chain reactions (qPCR) and segmented by treatment: control ( $n=6$ ),  $\alpha$ CTLA-4 ( $n=6$ ),  $\alpha$ PD-1 ( $n=6$ ), combined blockade ( $n=7$ ) and BsAb ( $n=8$ ). **i**, The number of viral lineages, as determined by sequencing of gp160 env, in plasma that reactivated on ART during ICB (left, 'Reactivation',  $n=8$ ) and during early rebound post-ATI (right, 'Rebound',  $n=8$ ) are shown. Viral lineages were deemed distinct if they differed by three or more nucleotide polymorphisms over gp160 env sequences. Individual RMs are indicated by shape with filled data points indicating viral reactivation in plasma. Averaged data are presented as mean  $\pm$  s.e.m. and were analyzed using a two-sided Wilcoxon matched-pairs signed rank test (**h**) or Mann-Whitney U test (**g**).

genomes per  $10^6$  CD4<sup>+</sup> cells, d-29 and d28 p.t., respectively). In comparison, all CTLA-4 blockades result in a fold change reduction in the frequency of intact provirus (Extended Data Fig. 7c,d),

which was most pronounced, relative to baseline, for dual CTLA-4/PD-1 blockade (combined blockade,  $P=0.0860$ ; BsAb,  $P=0.0255$ , Fig. 4c; representative data are shown in Extended Data Fig. 7e).



To define the anatomic localization of SIV-RNA<sup>+</sup> cells in LN, we employed RNAscope, an in situ hybridization assay to detect and quantify cells harboring SIV-RNA (vRNA<sup>+</sup>) by tissue location<sup>27</sup>. Only combined blockade showed a significant reduction in the number of vRNA<sup>+</sup> cells normalized per 10<sup>5</sup> cellular nuclei as compared to baseline ( $P=0.0312$ ; Extended Data Fig. 8a), which was confirmed specifically within the BCF ( $P=0.0312$ ; Fig. 4d,e) and not within the TCZ or the medullary cords (not shown). The decline in BCF-resident vRNA<sup>+</sup> cells in combination with heightened proliferative capacity in LN memory CD4<sup>+</sup> T cells (Fig. 2g) suggests that combined blockade has the potential to target and reduce a subset of cells undergoing viral reactivation. Finally, only BsAb-treated RMs showed a measurable decrease in vDNA<sup>+</sup> cells, quantified by DNAscope and normalized per 10<sup>5</sup> cells, in the BCF ( $P=0.0391$ ; Fig. 4f) and TCZ ( $P=0.0156$ , Fig. 4g; representative images are shown in Fig. 4h), and treatment did not differentially impact T cell or macrophage viral reservoirs (Extended Data Fig. 8b–d). As a caveat, DNAscope cannot distinguish between defective and intact viral genomes; however, we did observe a correlation between the reservoir content as determined by IPDA and DNAscope following therapy (Extended Data Fig. 8e). Collectively, these results highlight that, in lymphoid tissue, combined blockade limits SIV reservoir content within CD4<sup>+</sup> T<sub>EM</sub> concomitant with reduced viral production and persistence in the BCF, suggesting a direct link between viral reactivation and clearance in a fraction of infected cells.

**Dual CTLA-4/PD-1 blockade does not control or delay viral rebound after ATI.** To functionally assess the impact of ICB on the size of the viral reservoir we conducted an ATI two weeks after ICB cessation. Overall, there was a limited impact on delaying viral rebound, with  $\alpha$ PD-1 treatment ( $P=0.0390$ ) and dual CTLA-4/PD-1 blockade producing a slight delay in time to measurable viral rebound as compared to controls (control,  $7.67 \pm 0.82$  days;  $\alpha$ CTLA-4,  $8.00 \pm 0.52$  days;  $\alpha$ PD-1,  $12.83 \pm 2.04$  days; combined blockade  $10.29 \pm 1.69$  days; BsAb,  $12.75 \pm 3.48$  days; Extended Data Fig. 9a–f). Twelve of 13 RMs with prior ICB-mediated viral reactivation re-established undetectable plasma viremia between their terminal on-ART reactivation event and the first post-ATI observation, consistent with the observed on-ART viremia being LRA-mediated and not a failure of the ART regimen. All blockades failed to significantly attenuate the set-point plasma viral load post-ATI (Extended Data Fig. 9g), the fold change in peak viremia relative to acute infection (not shown) and the fold change in set-point viremia at necropsy (d170 post-ATI) relative to chronic infection (d52 p.i.; Extended Data Fig. 9h) as compared to controls. Furthermore, ICB failed to impact on cell-associated SIV-DNA or SIV-RNA levels, or their respective ratio in axillary LN or spleen at necropsy (Extended Data Fig. 9i and Supplementary Fig. 7). Of note, post-ATI viremia was associated with a robust induction of proliferation, activation

and CTL functionality in SIV-specific memory CD8<sup>+</sup> T cells relative to during ART, suggesting a critical dependence on sufficient antigen burdens (Extended Data Fig. 5g–j). Thus, the potent latency reversal and the partial reduction of the viral reservoir induced by combined CTLA-4 and PD-1 blockade under long-term ART is insufficient, alone, to control viral rebound after ART interruption.

Finally, single-genome sequencing of gp160 *env* was performed on plasma during on-ART, ICB-mediated viral reactivation ( $n=8$ ) and at rebound following ATI ( $n=8$ ). Qualitatively, all RMs across ICB treatments yielded a similar number of viral lineages during rebound (3–10 lineages; Fig. 3i), consistent with a polyclonal nature of the seeded, latent viral reservoir and rebound virus<sup>28</sup>. Only  $\alpha$ PD-1 monotherapy was associated with highly restricted clonality in reactivating virus (that is, a single lineage), whereas virus arising from  $\alpha$ CTLA-4 monotherapy (2–7 lineages) and dual blockade (combined blockade, 5–7 lineages; BsAb, 4–7 lineages) was polyclonal in nature (Fig. 3i and Extended Data Fig. 10). These data suggest that combination CTLA-4/PD-1 blockade was able to reactivate a larger and more diverse latent reservoir as compared to  $\alpha$ PD-1 monotherapy (Supplementary Table 3).

## Discussion

The quest for a functional cure for HIV is hampered by a limited understanding of the mechanisms underlying the long-term persistence of HIV reservoirs, including both latently and actively infected cells, the absence of reliable biomarkers for the selective targeting of latently infected cells, the lack of potent LRAs that induce robust viral reactivation during suppressive ART and the inhibition of HIV-specific cytotoxic T cell responses mediated by co-inhibitory signaling arising from chronic immune activation. The results of the current study indicate that CTLA-4 blockade, particularly when combined with PD-1 blockade, enhances activation, proliferation and expansion of LN and PB memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells, including T<sub>EM</sub> cells. In contrast, anti-PD-1 monotherapy showed limited effects on reversing the negative regulation of T cell activation. Of note, combined blockade potentially enhanced viral reactivation on ART, as measured by plasma viremia, among the most persistent published so far, and increased the levels of cell-associated SIV-RNA in PBMCs. Furthermore, RMs receiving combined CTLA-4/PD-1 blockade showed a greater number of reactivated viral lineages compared to anti-PD-1 monotherapy. These findings suggest that blocking CTLA-4 co-inhibitory signaling, especially in combination with PD-1 blockade, is critical to reverse latency in a larger subset of memory CD4<sup>+</sup> T cells during long-term ART.


Although combined blockade-induced proliferation provided an effective ‘shock’ to break viral latency in memory CD4<sup>+</sup> T cells, this treatment, as well as the  $\alpha$ CTLA-4 and  $\alpha$ PD-1 monotherapies, failed to induce a significant functional reversal of exhaustion. Previous in vivo PD-1 blockades in SIV-infected RMs have demonstrated

**Fig. 4 | CTLA-4 and dual blockade, but not PD-1 blockade, reduces the total and intact SIV-DNA in LN.** **a,b**, In LN, memory subsets in CD4<sup>+</sup> T cells were sorted at d28 p.t., shown in a representative gating strategy (1 of 33 single-replicate runs; RTj16) (**a**), and the cell-associated SIV-DNA content was determined via 12 replicate reaction qPCR with reverse transcription (RT-qPCR) (**b**). Within the memory CD4<sup>+</sup> T cells, the sorted populations are defined as follows: T<sub>HH</sub>, PD-1<sup>hi</sup>CD200<sup>hi</sup>; T<sub>REG</sub>, PD-1<sup>lo</sup>CD200<sup>lo</sup>CD127<sup>+</sup>CD25<sup>+</sup>; T<sub>CM</sub>, PD-1<sup>lo</sup>CD200<sup>lo</sup>CD25<sup>+</sup>CCR7<sup>+</sup>; T<sub>EM</sub>, PD-1<sup>lo</sup>CD200<sup>lo</sup>CD25<sup>+</sup>CCR7<sup>+</sup>. **c**, With eight replicate reaction intact proviral DNA assays (IPDAs), the numbers of intact proviral genomes per 10<sup>5</sup> CD4<sup>+</sup> cells were quantified in LN at pre-treatment baseline (d-29 p.t.) and following the fourth ICB (d28 p.t.): control ( $n=3$ ),  $\alpha$ CTLA-4 ( $n=6$ ),  $\alpha$ PD-1 ( $n=6$ ), combined blockade ( $n=7$ ) and BsAb ( $n=7$ ). **d,e**, By using RNAscope, the numbers of vRNA<sup>+</sup> cells per 10<sup>5</sup> cells were measured in the lymphoid B cell follicle (BCF) (**d**) and a representative stain is shown for vRNA (red) in the LN BCF both pre- and post-treatment (combined blockade-treated RVr16; 1 of 33 unique samples quantified from up to two tissue sections) (**e**). The distance scale is given below each panel with successive magnifications within the indicated area (black square) extending to the right. **f,g**, Using DNAscope, the numbers of vDNA<sup>+</sup> cells per 10<sup>5</sup> cells were quantified in the lymphoid BCF (**f**) and the T cell zone (TCZ) (**g**). **h**, A representative stain (BsAb-treated RKT16; 1 of 33 unique samples quantified from up to two tissue sections) is shown for vDNA (red). For all analyses, except IPDA as indicated, annotations and population sizes are as follows: controls ( $n=6$ ), black;  $\alpha$ CTLA-4 ( $n=6$ ), blue;  $\alpha$ PD-1 ( $n=6$ ), pink; combined blockade ( $n=7$ ), red; BsAb ( $n=8$ ), purple. Individual RMs are indicated by shape, with filled data points indicating viral reactivation in plasma. Averaged data are presented as mean  $\pm$  s.e.m. and were analyzed with a two-sided two-way analysis of variance (ANOVA) or a mixed-effect model with Dunnett’s correction relative to controls (**b**), Bonferroni’s corrections for multiple comparisons relative to baseline (**c**) or a Wilcoxon matched-pairs signed rank test (**d,f,g**).



marked enhancement of SIV-specific antiviral responses; however, they were conducted in the absence of ART<sup>16,29,30</sup> and either before ART initiation or during short-term ART with detectable viral loads<sup>17,29,31</sup>, suggesting that the presence of antigen at the time of PD-1 blockade is important for breaking the exhausted phenotype.

Consistently, PD-1 blockade failed to improve antiviral immune responses when performed in SIV-infected RMs after more than two years of ART<sup>18</sup>. PD-1 blockade was also shown to restore CTL responses in HIV-infected, ART-treated humans in vivo in the context of relapsing cancer with prior chemotherapy<sup>11,13</sup>; however, the



impact on the HIV reservoir and CTL function has been highly variable<sup>12</sup>. If ICB efficacy is dependent on a critical antigen concentration, restoration of HIV-specific responses may require extensive pretreatment with additional LRAs, as concurrent virus reactivation during ICB was not associated with CTL enhancement.

Dual CTLA-4/PD-1 blockade produced a significant reduction in cell-associated SIV-DNA within LN CD4<sup>+</sup> T<sub>EM</sub>, the CD4<sup>+</sup> T cell subpopulation most activated from combined treatment. Importantly, in situ hybridization assays demonstrated a significant reduction in the number of vRNA<sup>+</sup> and vDNA<sup>+</sup> cells following dual CTLA-4/PD-1 blockade in the LN, including in the BCF. Finally, dual CTLA-4/PD-1 reduced the frequency of LN CD4<sup>+</sup> cells harboring intact proviral DNA as determined by IPDA. Of note, PD-1 blockade alone did not impact any measure of viral persistence. We have previously shown that in ART-treated RMs a large fraction of LN CD4<sup>+</sup>PD-1<sup>+</sup> T cells that reside within the BCF that are preferentially enriched for vDNA also express CTLA-4<sup>1</sup>. Given their expression of both ICRs, these cells probably represent a preferentially responsive target to dual blockade. Together, these findings suggest a link between viral reactivation and clearance, at least in a subset of infected cells.

Following ART withdrawal, combined blockade did not impact the delay in viral rebound or the set-point viral load. In this regard, in the current study ART was initiated at d60 p.i., substantially later than in other NHP studies involving ATI, and therefore with a larger and more disseminated reservoir and development of T cell exhaustion<sup>32,33</sup>. The inability of the combined blockade to extend the  $\alpha$ PD-1 monotherapy-mediated five-day delay in viral rebound suggests that  $\alpha$ CTLA-4-driven T<sub>REG</sub> responses and/or some level of reservoir reseeding caused by viral reactivation may have been sufficient to abrogate the antiviral synergy between the two treatments<sup>34,35</sup>. Unexpectedly, dual CTLA-4/PD-1 blockade was well tolerated in NHP, whereas similar regimens were found to be associated with a substantial risk of serious immune-related adverse events in human clinical trials for cancer<sup>36–39</sup>. At present, it is unknown whether CTLA-4 or dual CTLA-4/PD-1 blockade would exhibit acceptable toxicity profiles in ART-treated people living with HIV without comorbidities. It is plausible that the onset of toxicity could be linked with factors such as the timing of intervention (that is, the presence and burden of antigen), the duration or interval of therapy, or the extent of T cell exhaustion (that is, the frequency and distribution of ICR expression). Our study highlights the need to better understand how tolerability changes in different preclinical and clinical settings while balancing the need for immunological efficacy with acceptable profiles of toxicity.

This study represents the first in vivo combined ICB in SIV-infected, ART-treated RMs with a high barrier for cure, designed to mimic issues pertaining to treatment in people living with HIV, albeit with a shorter duration of ART than would be expected in humans. We have demonstrated that CTLA-4 blockade in SIV-infected, ART-treated RMs produces robust T cell proliferation and T<sub>EM</sub> expansion that synergizes with PD-1 blockade to enhance viral reactivation in PBMCs and plasma, decrease the SIV-DNA content in LN T<sub>EM</sub>, reduce the number of vDNA<sup>+</sup> and RNA<sup>+</sup> cells in the LN BCF and limit the levels of intact provirus in LN. Thus, combined ICB induces latency reversal and a partial reduction of the reactivated reservoir, two critical steps towards eradication of the persistent reservoir of latently HIV-infected cells. Our data highlight the possibility that re-invigoration of antiviral responses through relieving T cell exhaustion may be dependent on antigen burden. As such, ICB might be more beneficial in antigen-rich phases of HIV infection (such as during ATI or at the time of ART initiation), in subjects that started ART in acute infection (to limit the extent of T cell exhaustion and viral reservoir seeding) or in combination with enhanced killing strategies, such as therapeutic vaccinations<sup>40</sup> or co-administration of neutralizing antibodies<sup>28</sup>. The current study

indicates that ICB, even when targeting both PD-1 and CTLA-4, is unlikely to induce HIV remission if performed in the context of sustained aviremia and in the absence of additional interventions.

## Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-020-0782-y>.

Received: 14 June 2019; Accepted: 28 January 2020;

Published online: 16 March 2020

## References

- McGary, C. S. et al. CTLA-4<sup>+</sup>PD-1<sup>+</sup> memory CD4<sup>+</sup> T cells critically contribute to viral persistence in antiretroviral therapy-suppressed, SIV-infected rhesus macaques. *Immunity* **47**, 776–788 (2017).
- Banga, R. et al. PD-1<sup>+</sup> and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. *Nat. Med.* **22**, 754–761 (2016).
- Fromentin, R. et al. CD4<sup>+</sup> T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. *PLoS Pathog.* **12**, e1005761 (2016).
- Perez, V. L. et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. *Immunity* **6**, 411–417 (1997).
- Fife, B. T. & Bluestone, J. A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. *Immunol. Rev.* **224**, 166–182 (2008).
- Perreau, M. et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication and production. *J. Exp. Med.* **210**, 143–156 (2013).
- Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature* **443**, 350–354 (2006).
- Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8<sup>+</sup> T cells leads to reversible immune dysfunction. *Nat. Med.* **12**, 1198–1202 (2006).
- Wightman, F. et al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. *AIDS* **29**, 504–506 (2015).
- Evans, V. A. et al. Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. *AIDS* **32**, 1491–1497 (2018).
- Guihot, A. et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. *Ann. Oncol.* **29**, 517–518 (2018).
- Scully, E. P. et al. Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. *Ann. Oncol.* **29**, 2141–2142 (2018).
- Le Garff, G. et al. Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. *AIDS* **31**, 1048–1051 (2017).
- Cecchinato, V. et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. *J. Immunol.* **180**, 5439–5447 (2008).
- Hryniewicz, A. et al. CTLA-4 blockade decreases TGF- $\beta$ , IDO and viral RNA expression in tissues of SIVmac251-infected macaques. *Blood* **108**, 3834–3842 (2006).
- Velu, V. et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. *Nature* **458**, 206–210 (2009).
- Mylvaganam, G. H. et al. Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV. *JCI Insight* **3**, 122940 (2018).
- Bekerman, E. et al. PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy. *Antimicrob. Agents Chemother.* **63**, e01163-19 (2019).
- Wang, C. et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558 and in vivo toxicology in non-human primates. *Cancer Immunol. Res.* **2**, 846–856 (2014).
- Hardtke, S., Ohl, L. & Forster, R. Balanced expression of CXCR5 and CCR7 on follicular T helper cells determines their transient positioning to lymph node follicles and is essential for efficient B-cell help. *Blood* **106**, 1924–1931 (2005).
- Velu, V. et al. Induction of Th1-biased T follicular helper (Tfh) cells in lymphoid tissues during chronic simian immunodeficiency virus infection defines functionally distinct germinal center Tfh cells. *J. Immunol.* **197**, 1832–1842 (2016).
- Pearce, E. L. et al. Control of effector CD8<sup>+</sup> T cell function by the transcription factor eomesodermin. *Science* **302**, 1041–1043 (2003).
- Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. *Immunity* **51**, 840–855 (2019).

24. Fromentin, R. et al. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4<sup>+</sup> T cells from ART-suppressed individuals. *Nat. Commun.* **10**, 814 (2019).
25. Estes, J. D. et al. Defining total-body AIDS-virus burden with implications for curative strategies. *Nat. Med.* **23**, 1271–1276 (2017).
26. Bender, A. M. et al. The landscape of persistent viral genomes in ART-treated SIV, SHIV and HIV-2 infections. *Cell Host Microbe* **26**, 73–85 (2019).
27. Deleage, C. et al. Defining HIV and SIV reservoirs in lymphoid tissues. *Pathog. Immun.* **1**, 68–106 (2016).
28. Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. *N. Engl. J. Med.* **375**, 2037–2050 (2016).
29. Amancha, P. K. et al. In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses but has limited clinical benefit. *J. Immunol.* **191**, 6060–6070 (2013).
30. Dyavar Shetty, R. et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. *J. Clin. Invest.* **122**, 1712–1716 (2012).
31. Finnefrock, A. C. et al. PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. *J. Immunol.* **182**, 980–987 (2009).
32. Okoye, A. A. et al. Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. *Nat. Med.* **24**, 1430–1440 (2018).
33. Borducchi, E. N. et al. Publisher correction: antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. *Nature* **564**, E8 (2018).
34. Weiss, L. et al. Human immunodeficiency virus-driven expansion of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. *Blood* **104**, 3249–3256 (2004).
35. Nilsson, J. et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. *Blood* **108**, 3808–3817 (2006).
36. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N. Engl. J. Med.* **373**, 23–34 (2015).
37. Hao, C. et al. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* **96**, e7325 (2017).
38. Koelzer, V. H. et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study. *J. Immunother. Cancer* **4**, 13 (2016).
39. Cook, M. R. & Kim, C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. *JAMA Oncol.* **5**, 1049–1054 (2019).
40. Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. *Nature* **473**, 523–527 (2011).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



## Methods

**Animals, SIV infection and ART.** Thirty-four male Indian RMs (*Macaca mulatta*), all housed at the Yerkes National Primate Research Center (YNPRC), were included in this study. All RMs were *Mamu-B\*07*<sup>+</sup> and *Mamu-B\*17*<sup>+</sup>, with the following being *Mamu-A01*<sup>+</sup>: RGi16, RK16, RVr16, RHn16, RPo16 and RZw15. RMs were screened for pathogens and housed as previously described<sup>1</sup>.

All RMs were infected i.v. with 300 TCID<sub>50</sub> SIVmac<sub>239</sub> (Fig. 1a). At 60 days p.i., all RMs initiated a daily ART regimen consisting of DTG (2.5 mg kg<sup>-1</sup> d<sup>-1</sup>, subcutaneous (s.c.)), TDF (5.1 mg kg<sup>-1</sup> d<sup>-1</sup>, s.c.) and FTC (40 mg kg<sup>-1</sup> d<sup>-1</sup>, s.c.)<sup>41</sup>, maintained for up to 13.5 months (Extended Data Figs. 1 and 2a). RMs were then stratified into treatment groups based on their projected time of virologic suppression under ART, *Mamu-A\*01* status and presence of ADAs during chronic infection (d52 p.i.; Supplementary Fig. 1 and Supplementary Table 1). After a minimum of three discontinuous months of undetectable plasma viral loads (181.4 ± 4.9 days; limit of detection ≤ 60 copies per ml) animals were administered ICB mAbs once per week over four weeks. After a two-week washout period, RMs underwent an ART ATI and were followed for up to seven months with a subsequent necropsy. RFI16 was euthanized at d25 p.i. due to rapid progression to AIDS-defining endpoints, specifically attributable to weight loss.

**Study approval.** All animal experimentation was conducted under anesthesia with follow-up pain management following guidelines set forth by the Animal Welfare Act and by the NIH's Guide for the Care and Use of Laboratory Animals (8th edition). All studies were conducted in accordance with institutional regulations including GSK's Policy on the Care, Welfare and Treatment of Laboratory Animals, and were reviewed and approved by Emory's Institutional Animal Care and Use Committee (IACUC; permit nos. 3000065, 2003297, 2003470 and PROTO201700665). Animal care facilities at YNPRC are accredited by the US Department of Agriculture (USDA) and the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.

**Immune checkpoint blockade.** ICR blocking mAbs were developed, formulated and produced by GlaxoSmithKline and provided via Qura Therapeutics. The described therapeutics are the intellectual property of GlaxoSmithKline and are not commercially available. VHDUM, the control, is a fully human IgG1 mAb with the Fc region disabled by the LAGA mutations L235A and G237A. The mAb portion has the sequence of palivizumab (anti-respiratory syncytial virus, MAbImmune) and is linked by a fibronectin linker to an irrelevant domain antibody that has no known specificity. The IgG4 anti-PD-1 mAb (αPD-1) is a biosimilar formulation of nivolumab (Bristol-Myers Squibb) with a human variable region and a rhesus constant region. The IgG1 anti-CTLA-4 mAb (αCTLA-4) is a fully human, biosimilar formulation of ipilimumab (Bristol-Myers Squibb) that retains Fcγ binding activity. The IgG1 bispecific αCTLA-4/αPD-1 mAb (BsAb) has a human variable and rhesus constant region with a LAGA mutation-disabled Fc receptor, and was constructed with a flexible fibronectin linker connecting the C terminus of the mAb heavy chain to a PD-1 domain antibody (dAb)<sup>42</sup>. The antagonistic anti-PD-1 dAb was identified through phage display, and bound PD-1-expressing cells with a half-maximum effective concentration of 2 nM, thereby efficiently blocking interactions with PDL-1/PDL-2<sup>43</sup>. The BsAb CTLA-4 is biosimilar to ipilimumab and the PD-1 is a proprietary formulation of GlaxoSmithKline (Extended Data Fig. 2b). Optimal dosing concentrations and intervals were determined in a pharmacokinetics and pharmacodynamics pilot study in drug-naïve, uninfected RMs conducted by Convince Research Products on behalf of GlaxoSmithKline (data not shown).

Pre-filtered, endotoxin-free compounds were provided in sterile, glass dosing vials that were stored long-term at -80 °C. Agents were administered under anesthetic sedation as an i.v. bolus push over ~15 min without pretreatment prophylaxis. Doses administered were as follows: control, 30 mg kg<sup>-1</sup> (n = 6); αCTLA-4, 5 mg kg<sup>-1</sup> (n = 6); αPD-1, 5 mg kg<sup>-1</sup> (n = 6); αCTLA-4 plus αPD-1 (combined blockade), 5 mg kg<sup>-1</sup> each (n = 7); BsAb, 5 mg kg<sup>-1</sup> (n = 8). Diphenhydramine (1–2 mg kg<sup>-1</sup>, i.v.) and dexamethasone (0.3 mg kg<sup>-1</sup>, i.v.) were available in the event of a suspected adverse event, such as anaphylaxis or respiratory distress. Endpoint criteria included the onset of adverse events that required steroids to control.

**Sample collection and processing.** Collections of PB and LN biopsies were conducted longitudinally and at necropsy (Fig. 1a) as previously described<sup>1</sup> with the following exception: during ICB infusions, blood was drawn prior to and 5 min afterwards for pharmacokinetic assays.

**Flow cytometric analysis.** An 18-parameter flow cytometric analysis was performed on PBMCs and mononuclear cells derived from LN biopsies. Samples were stained utilizing standard procedures with anti-human mAbs that we, and others, have shown to be cross-reactive in RMs<sup>1,44</sup>, and those clones verified as RM reactive (NHP Reagent Resource). The following antibodies were used at predetermined optimal concentrations for the longitudinal staining panel: anti-Tbet-PE/Dazzle-594 (clone 4B10, cat. no. 644828), anti-FoxP3-APC (clone 150D, cat. no. 320014), anti-CD4-APC-Cy7 (clone OKT4, cat. no. 317418), anti-CD95-BV605 (clone DX2, cat. no. 305628), anti-HLA-DR-BV650 (clone L243, cat. no. 307650),

anti-CD25-BV711 (clone BC96, cat. no. 302636), anti-CD20-PerCP/Cy5.5 (clone 2H7, cat. no. 302326) and anti-PD-1-BV785 (clone EH12.2H7, cat. no. 329930) (all from Biolegend); anti-CXCR5-PE (clone MUSUBEE, cat. no. 12-9185-42) and anti-CD127-PE-Cy5 (clone eBioRDR5, cat. no. 15-1278-42) (eBioscience); anti-CCR7-PE-Cy7 (clone 3D12, cat. no. 557648), anti-Ki-67-Alexa700 (clone B56, cat. no. 561277), anti-CTLA-4-BV421 (clone BNI3, cat. no. 562743), anti-CD3-BUV395 (clone SP34-2, cat. no. 564117), anti-CD8-BUV496 (clone RPA-T8, cat. no. 564804) and anti-CD28-BUV737 (clone CD28.2, cat. no. 564438) (BD Biosciences); anti-LAG-3-FITC (clone 17B4, cat. no. NBP1-97665) (Novus Biologicals); Aqua Live/Dead amine dye-AmCyan from Invitrogen (cat. no. L34966). The following antibodies were used for phenotyping cryo-preserved LN: anti-CD200-PE (clone OX104, cat. no. 329206), anti-HLA-DR-PE-Cy5 (clone L243, cat. no. 307608), anti-CD4-APC-Cy7 (clone OKT4, cat. no. 317418), anti-CD25-BV711 (clone BC96, cat. no. 302636), anti-CD101-PerCP/Cy5.5 (clone BB27, cat. no. 331016), anti-CD95-BV605 (clone DX2, cat. no. 305628) and anti-CD69-BV785 (clone FN50, cat. no. 310932) (Biolegend); anti-CD38-FITC (clone AT-1, cat. no. 10415) (STEMCELL Technologies); anti-CCR7-PE-Cy7 (clone 3D12, cat. no. 557648), anti-Ki-67-Alexa700 (clone B56, cat. no. 561277), anti-CTLA-4-BV421 (clone BNI3, cat. no. 562743), anti-CXCR3-BV650 (clone 1C6/CXCR3), anti-CD3-BUV395 (clone SP34-2, cat. no. 564117), anti-CD8-BUV496 (clone RPA-T8, cat. no. 564804) and anti-CD28-BUV737 (clone CD28.2, cat. no. 564438) (BD Biosciences); anti-PD-1-Alexa647 (clone 913429, cat. no. MAB10861; 1:50 dilution) (Novus Biologicals); anti-Granzyme B-PE-Texas Red (clone GB11, cat. no. GRB17) and Aqua Live/Dead amine dye-AmCyan (cat. no. L34966) (Invitrogen). The following panel of antibodies was utilized for measuring cytolytic and SIV-specific responses in cryo-preserved cells: anti-CD3-BUV395 (clone SP34-2, cat. no. 564117), anti-CD8-BUV496 (clone RPA-T8, cat. no. 564804), anti-Ki-67-AL700 (clone B56, cat. no. 561277), anti-CD95-PE-Cy5 (clone DX2, cat. no. 559773), anti-CCR7-BV480 (clone 3D12, cat. no. 566099), anti-Granzyme B-BV421 (clone GB11, cat. no. 563389) and anti-CD28-BUV737 (clone CD28.2, cat. no. 612815) (BD Biosciences); anti-HLA-DR-BV750 (clone L243, cat. no. 307672), anti-CD4-BV570 (clone OKT4, cat. no. 317445), anti-PD-1-BV786 (clone EH12.2H7, cat. no. 329930) and anti-CTLA-4-PE (clone BNI3, cat. no. 369604) (Biolegend); anti-Gag-APC (clone CM9, 4.2 µg per test) from the NIH Tetramer Facility at Emory University<sup>45</sup>; anti-CD38-APC (clone AT-1, cat. no. 60131FI) (STEMCELL Technologies); anti-EOMES-PE-eFluor610 (clone WD1928, cat. no. 611-4877-42) and LIVE/DEAD Fixable Near-IR Dead Cell Stain (cat. no. L34976) (Thermo Fisher Scientific). All mAbs were used at the manufacturer's recommended test volume per 10<sup>6</sup> mononuclear cells (1:100 dilution) unless otherwise noted.

Purified anti-PD-1 (clone 913429, cat. no. MAB10861; Novus Biologicals) was labeled using an Alexa Fluor 647 Antibody Labeling Kit (Invitrogen) using the manufacturer's guidelines. To detect intracellular expression of FoxP3, mononuclear cells were fixed and permeabilized with FoxP3/Transcription Factor Staining Buffer Kit Fix/Perm (Tonbo), and subsequently stained intracellularly; otherwise a BD Cytofix/Cytoperm kit (BD Biosciences) was employed. To determine the *ex vivo* expression of CTLA-4<sup>+</sup> in CD4<sup>+</sup> and CD8<sup>+</sup> T cells, staining was performed intracellularly in unstimulated T cells<sup>1</sup>. Flow cytometry acquisition was performed on a minimum of 120,000 live CD3<sup>+</sup> T cells for LN and PBMCs. Data acquisition was performed on an LSRFortessa or FACSymphony (BD Biosciences) driven by FACS DiVa software and analyzed using FlowJo software (version 9.9.6, TreeStar).

**Flow cytometry cell sorting.** Cryo-preserved, unstimulated mononuclear cells derived from LN biopsies were stained with the following combination of RM-reactive, anti-human mAbs (NHP Reagent Resource)<sup>1,44</sup>: anti-CD200-PE (clone OX104, cat. no. 329206), anti-CD25-Alexa700 (clone BC96, cat. no. 302622) and anti-CD4-BV650 (clone OKT4, cat. no. 317436) (Biolegend); anti-CD28-PE-CF594 (clone CD28.2, cat. no. 562296), anti-CCR7-PE-Cy7 (clone 3D12, cat. no. 557648), anti-CD3-APC-Cy7 (clone SP34-2, cat. no. 557757) and anti-CD95-BV421 (clone DX2, cat. no. 562648) (BD Biosciences); anti-CD8-FITC (clone 3B5, cat. no. MHCD0801) and Aqua Live/Dead amine dye-AmCyan (cat. no. L34966) (Invitrogen); anti-CD127-PE-Cy5 (clone eBioRDR5, cat. no. 15-1278-42) (eBioscience); anti-PD-1-Alexa647 (clone 913429, cat. no. MAB10861; 1:50 dilution) (Novus Biologicals). All mAbs were used at the manufacturer's recommended test volume (1:100 dilution) scaled per 10<sup>7</sup> mononuclear cells unless otherwise noted. Purified anti-PD-1 was labeled using an Alexa Fluor 647 Antibody Labeling Kit (Invitrogen) using the manufacturer's guidelines. The following memory subsets of CD4<sup>+</sup> T cells were sorted on a fluorescence-activated cell sorting (FACS) Aria II system (BD Biosciences): T<sub>HH</sub>, T<sub>REG</sub>, T<sub>EM</sub> and T<sub>CM</sub>. For phenotypic discrimination, T<sub>HH</sub> were defined as PD-1<sup>hi</sup>CD200<sup>hi</sup>, whereas T<sub>REG</sub> (CD25<sup>+</sup>CD127<sup>-</sup>) were pre-gated as PD-1<sup>hi</sup>CD200<sup>hi</sup> to avoid inclusion of CD25<sup>+</sup>T<sub>HH</sub> cells and T follicular regulator (T<sub>REG</sub>) cells<sup>46</sup>. Within the CD25<sup>+</sup>PD-1<sup>hi</sup>CD200<sup>hi</sup> population, T<sub>EM</sub> and T<sub>CM</sub> were sorted based on their CCR7 expression. Sorted CD4<sup>+</sup> T cell subsets were on average >96% pure as determined by post-sorting flow cytometry analysis. See Fig. 4a for a representative gating strategy.

**Determination of viral load RNA.** The number of SIVmac<sub>239</sub> RNA copies per ml of plasma was quantified, as previously described, by RT-qPCR<sup>47</sup> or by PCR<sup>48</sup> with a limit of detection of 15 copies per ml and 60 copies per ml, respectively; therefore, the higher limit of detection was utilized for all datasets.

**Quantitation of cell-associated SIV-DNA and SIV-RNA.** Analyses were performed on FACS-sorted memory CD4<sup>+</sup> T cell subsets from LN biopsies and on bulk snap-frozen PBMCs. SIV-DNA and SIV-RNA were extracted using an AllPrep DNA/RNA Mini Kit (Qiagen). SIV-DNA and SIV-RNA in tissue was assessed using hybrid real-time/digital PCR and RT-qPCR assays in 12 replicate reactions with single-copy clinical sensitivity, as previously described<sup>49</sup>. Viral copy numbers were reported normalized based on CCR5 DNA copy numbers. Assays for which there were fewer than 10 positive amplifications per replicates were calculated using Poisson methods.

**Chromogenic SIV-RNA and SIV-DNA in situ hybridization and image analysis.** RNAscope was performed on formaldehyde-fixed, paraffin-embedded (FFPE) tissue sections (5 mm) according to our previously published protocol<sup>27</sup> with the following minor modifications: heat-induced epitope retrieval was performed by boiling slides in 1× target retrieval (322000, ACD) for 30 min, followed by incubation at 40°C with a 1:10 dilution of protease III (322337, ACD) in 1× phosphate buffered saline (PBS) for 20 min. Slides were incubated with the target probe SIVmac<sub>239</sub> (312811, ACD) for 2 h at 40°C. Amplification was performed with RNAscope 2.5 HD Detection kits (322360, ACD) according to the manufacturer's instructions with 0.5× wash buffer (310091, ACD) used between steps. The resulting signal was detected with Warp Red chromogen (WR806M, Biocare Medical). Slides were counterstained with CAT hematoxylin (CATHE-GL, Biocare Medical), mounted with Clearmount (17885-15, EMS) until dry, cover slipped using Permount (SP15-100, Fisher Scientific) and scanned at ×40 magnification on an Aperio AT2 system (Leica Biosystems). DNAscope was performed on FFPE tissue sections as above except that a 1:5 dilution of protease III and an in-house 3% H<sub>2</sub>O<sub>2</sub> in PBS solution were used, slides were incubated with the target probe SIVmac<sub>239</sub> sense (314071, ACD) for 4 h at 40°C, and the wash steps after amplification steps 5 and 6 were performed using 1× Tris-buffered saline with 0.05% Tween 20 (TBS-T).

Quantitative image analysis of RNAscope whole-tissue images was performed to determine the total number of SIV vRNA<sup>+</sup> cells per 10<sup>5</sup> total cells using the CytoNuclear module (v1.6) within Halo software (v2.3.2089.27, Indica Labs). Specific regions of the LN (B cell follicle, T cell zone and medullary cord) were manually highlighted in Halo based on CD4/CD20 staining of subjacent slides. Using the Stain 1Min OD slider in the CytoNuclear module on concomitantly assayed, early chronic infection SIV<sup>+</sup> control slides, we set the vRNA minimum signal size to exclude detection of the smaller single vRNA and/or vDNA molecules. DNAscope images were analyzed for the total number of vDNA<sup>+</sup> cells per 10<sup>5</sup> total cells using the ISH module (v3.0.2; for quantifying the number of vDNA<sup>+</sup> cells) and the CytoNuclear module (v1.6; for quantifying the number of total cells) within Halo. We set the vDNA minimum and maximum signal spot sizes by adjusting the Probe 1 spot size setting in the ISH 3.0.2 module on SIV<sup>+</sup> control slides to capture only cells with one, and occasionally more than one, clear punctate dots within their nuclei. In all quantifications, manual curation was performed on each sample to correct for false positives and false negatives. Analyses were performed blinded for ICB therapy.

**Fluorescence multiplex SIV-RNA and SIV-DNA in situ hybridization with CD3 and myeloid cell staining and image analysis.** DNAscope and RNAscope were performed sequentially as described above, with the following modifications: for DNAscope, slides were kept wet following paraffin removal and antigen retrieval prior to the addition of the SIVmac<sub>239</sub> sense (314071, ACD) probe for 14 h at 40°C. Amplification was performed with the RNAscope 2.5 HD Detection kit-Brown (322310, ACD) and the signal was developed with tyramide-conjugated Alexa Fluor 647 (B40958, Invitrogen). Slides were placed for 10 min in 1× target retrieval (322000, ACD) at 95°C, cooled and probed for 2 h with SIVmac<sub>239</sub> (312811, ACD). Following amplification as above, the signal was developed with tyramide-conjugated Alexa Fluor 568 (B40956, Invitrogen). Slides were then incubated overnight with antibodies against the myeloid markers CD68 (CM033C, Biocare) and CD163 (MA5-11458, Invitrogen) at 1:400 each, and the T cell marker CD3 (RM-9107-S, Thermo Scientific) at 1:200, and detected with donkey anti-mouse Alexa Fluor 488 (A21202, Invitrogen) and donkey anti-rabbit DyeLight 755 (SA5-10043, Invitrogen) at 1:500 for 1 h, respectively.

To quantify the number of SIV vDNA<sup>+</sup> lymphocytes or myeloid cells on stained tissues, whole-slide high-resolution fluorescent scans were performed at ×20 using the Zeiss AxioScan Z.1 slide scanner. DAPI, Alexa Fluor 488, Cy5 (for Alexa Fluor 647) and Cy7 (for Alexa Fluor 750) channels were used to acquire images. The exposure time for image acquisition was between 4 and 150 ms. Multi-spectral images were analyzed using the HALO 2.3 platform (Indica Labs) using the following analysis methods: for SIV vDNA, cells with clear punctate dots were quantified using the module FISH v1.1.1. using a similar thresholding method as in the analysis of the chromogenic staining. Putative positive signals were further selected by fine filtering based on signal area and average intensity. For quantification of SIV vRNA<sup>+</sup> cells, the same FISH v1.1 module was also used with a minimum signal size set to exclude cells with single vRNA/vDNA signals. Manual curation was performed on each sample to correct for false positives and negatives. High-resolution representative images were taken using the Keyence BZ-X710 fluorescence microscope with the ×20 objective using the Z-stack and Full Focus functions. The exposure time for image acquisition was between 2 ms and 10 s.

**Quantification of anti-drug antibodies in plasma.** Plasma samples collected before and after antibody infusion were thawed, mixed with assay diluent (casein in PBS, Thermo Fisher Scientific), and added to the assay plate along with two concentrations (low and high) of the positive control (JDC-10, Southern Biotech) and a negative control (pool of normal RM plasma). Each antibody was biotinylated and sulfo-tagged with a 1:1 mixture of biotin-Ab and sulpho-tag-Ab at 1 µg ml<sup>-1</sup> in casein and added to the assay plate. The assay plate was sealed and placed on a shaker for more than 2 h at room temperature to allow complex formation. During the incubation, blocking buffer (Smartblock, Candor Biosciences) was added to a Meso Scale Discovery (MSD) standard streptavidin plate for 2 h at room temperature with shaking. Blocking solution was removed from the MSD-SA plate and a 50 µl volume of sample from the assay plate was added in duplicate to MSD-SA blocked plates. Plates were sealed, incubated in the dark for 1 h with continuous shaking, washed three times with 300 µl PBS with 0.1% Tween 20, and MSD read buffer was added. Plates were read on an MSD Imager and the levels of anti-drug antibodies were quantified by electrochemiluminescence (ECL).

#### Determination of pharmacokinetics of monoclonal antibodies in plasma.

The respective antigen (CTLA-4 or PD-1 protein) was diluted into PBS and coated onto each well of a microtiter plate for at least 12 h at 4°C. Plates were washed five times with 25 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.5 (wash buffer). A 150 µl volume of blocking assay buffer (Superblock TBS-T20, Thermo Fisher Scientific) was added and the plates were sealed and incubated for at least 1 h with constant shaking. Plasma samples collected pre- and 5 min post-infusion were serially diluted 50-fold into assay buffer. Samples needing further dilution were diluted into assay buffer containing 2% cynomolgus macaque serum. After washing, sample was added to each well of the microtiter plate as appropriate: test sample, blank, calibration standard or quality controls (that is, antibody diluted into plasma from healthy RMs, Bioreclamation). Plates were sealed and incubated with constant shaking for 2 h at 37°C. Plates were then washed, detection solution was added (ruthenium-labelled mouse anti-human IgG Fc JDC-10 from Southern Biotech or ruthenium-labelled PD-1 from GSK), and plates were incubated with constant shaking for 1 h at 37°C. Plates were once again washed, read buffer T (Meso Scale Discovery) was added to each well, and plates were read within 5 min on an MSD Sector S600 instrument.

**ELISpot for the quantification of IFN-γ response upon SIV-Gag and SIV-Env stimulation.** Cryo-preserved PBMCs and LN-derived mononuclear cells were thawed, rested and triplicate-plated at 4 × 10<sup>5</sup> cells per well. Cells were either unstimulated (DMSO) or stimulated with SIVmac<sub>239</sub> overlapping Gag/Env peptides (NIH AIDS Reagent Program) at a concentration of 1 µg ml<sup>-1</sup>, or with concanavalin A (Sigma) at 2.5 µg ml<sup>-1</sup>. Plates were incubated for 24 h at 37°C and the number of cells secreting IFN-γ were evaluated using the Monkey IFN-γ ELISpot<sup>PLUS</sup> kit (MABTECH) according to the manufacturer's instructions. The number of spot-forming units (SFUs) per well was enumerated on an ELISpot plate reader and expressed as SFUs per million cells. The IFN-γ response is shown as an average of triplicate reactions with the DMSO background subtracted out.

**Determination of intracellular cytokine induction following SIV-Gag and SIV-Env peptide stimulation.** Cryo-preserved PBMCs were thawed, rested and resuspended in RPMI 1640 (Invitrogen) supplemented with 10% FBS (Seradigm) in the presence of Golgi transport inhibitors, anti-CD107a-APC (clone H4A3, cat. no. 328620) from Biolegend, anti-CD49D (clone 9F10, cat. no. 304302) from BD Biosciences and anti-CD28-PE-Cy7 (clone CD28.2, cat. no. 25-0289-42) from eBiosciences. PBMCs were either left unstimulated (DMSO) or stimulated for 6 h at 37°C with either SIVmac<sub>239</sub> overlapping Gag/Env peptides (NIH AIDS Reagent Program) at a concentration of 1 µg ml<sup>-1</sup> or staphylococcal enterotoxin A & B (SEB/A-List Biologicals) at 250 ng ml<sup>-1</sup>. After stimulation, cells were washed and stained for cell surface antigens with the following combination of mAbs: anti-CD3 Alexa700 (clone SP34-2, cat. no. 557917), anti-CD95 BB515 (clone DX2, cat. no. 564596) and anti-CD4 BV711 (clone L200, cat. no. 563913) (BD Biosciences); anti-CD8 PerCP-Cy5.5 (clone RPA-T8/SK1, cat. no. 344710) and anti-PD-1 BV421 (clone EH12, cat. no. 329920) (Biolegend); Live/Dead Amine Aqua Dye (cat. no. L34966) (Life Technologies). To detect intracellular expression of cytokines, mononuclear cells were fixed and permeabilized with a Cytofix/Cytoperm kit (BD Biosciences) and stained as follows: anti-TNF-α BV650 (clone Mab11, cat. no. 563418) and anti-IL-2 PE (clone MQ1-17H12, cat. no. 500307) (Biolegend) and anti-IFN-γ PE-CF594 (clone B27, cat. no. 562392) (BD Biosciences). All mAbs were used at the manufacturer's recommended test volume (1:100 dilution). The frequency of SIV-specific memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells producing single or multiple cytokines was determined after background subtraction. Cytokine co-expression data were processed using Pestle and SPICE version 6 (NIAID)<sup>50</sup>.

**IPDA.** From LN biopsy-derived, cryo-preserved mononuclear cells, CD4<sup>+</sup> cells were isolated using non-human primate CD4 Microbeads (Miltenyi Biotec) and genomic DNA was extracted with a QIAamp DNA Mini Kit (QIAGEN). The IPDA was performed as described in refs. <sup>26,51</sup> with modifications. As the SIV IPDA was originally designed for SIVmac<sub>251</sub>, we adjusted the reverse primer for *env* to match

the SIVmac<sub>239</sub> consensus sequence: 5'-GTTGTATTGATTTTGTCAATCCC-3' (NCBI GenBank, accession no. M33262). Eight replicate wells of 500 ng DNA each were combined with 2× ddPCR Supermix for Probes (no dUTP, Bio-Rad) and primer/probe sets for regions in *pol* and *env* that favors amplification of intact proviral genomes. In addition, eight replicate wells of 500 ng DNA each were combined with ddPCR Supermix and primer/probe sets for 2-LTR circles and intact *env*, as described. Droplets were generated on the Automated Droplet Generator (Bio-Rad) and subsequently underwent thermocycling for 10 min at 95 °C for 45 cycles (30 s at 94 °C and 60 s at 57 °C per cycle) and 10 min at 98 °C. Droplets were read on the QX100 Droplet Reader (Bio-Rad). Replicate wells were merged and analyzed in the QuantaSoft Analysis Pro Software. As described by Bender and others, a correction for shearing was not applied given low and similar shearing rates across samples, and the frequency of 2-LTR<sup>+</sup>*env*<sup>+</sup> circles was subtracted from the frequency of intact (*pol*<sup>+</sup>*env*<sup>+</sup>) proviruses<sup>26,52</sup>. Samples with a DNA shearing index >25 were excluded from analyses (RWs16 at d-29 p.t.; Extended Data Fig. 7c), and limited cell numbers prevented analyses in three control and one BsAb-treated RMs.

**Genome sequencing.** Single-genome sequencing of gp160 *env* sequences were generated as previously described<sup>53</sup>. Briefly, plasma was centrifuged, vRNA was extracted using the EZ1 Virus Mini Kit v2.0 (Qiagen) and cDNA was synthesized using reverse primer SHIV.Env.R1 (5'-TACCCCTACCAAGTCATCA-3') and used for limiting-dilution nested PCR. Amplicons of the correct size were sequenced using the MiSeq platform (Illumina). Raw reads were aligned to the SIVmac<sub>239</sub> reference using Geneious version R11. Sequences with evidence of mixed templates were excluded from further analysis. Maximum-likelihood phylogenetic trees were generated using the HKY85 substitution model and a transition/transversion ratio of four in PhyML Version 3.0 (ATGC Bioinformatics) and visualized in FigTree<sup>54</sup>. Lineages were deemed distinct if they differed at three or more nucleotide positions over *env*. Sequences are available in GenBank (accession nos. MN856887–MN857133).

Sequencing was performed on plasma from chronic infection before ART initiation (d52 p.i.; *n*=2), during on-ART, ICB-mediated viral reactivation (*n*=8) and immediately following ATI (*n*=8). A total of 248 sequences (median 13 per sample) were obtained. During chronic infection (d52 p.i.) RTJ16 and RZL16 had a maximum divergence from the SIVmac<sub>239</sub> inoculum strain of 6 and 8 nucleotides (0.2–0.3%) and a maximum diversity of 9 and 13 nucleotides (0.3–0.5%), respectively. This degree of diversity enables enumeration of virus lineages, which provides a minimum estimate of the number of infected cells contributing to plasma viremia during ICB reactivation and rebound post-ATI.

**CellTrace proliferation tracking.** Cryo-preserved PBMCs were thawed, rested overnight and washed with PBS. Cells were labeled with 5 μM CellTrace Violet (cat. no. C34557, Thermo Fisher Scientific) in PBS at 37 °C in a dark water bath and quenched for 5 min over ice in the presence of 10% FBS (Gemini Bio-products). CellTrace-labeled PBMCs were washed and resuspended (2.5 × 10<sup>6</sup> cells per ml) in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 100 U ml<sup>-1</sup> penicillin, 100 μg ml<sup>-1</sup> streptomycin, 20 U ml<sup>-1</sup> recombinant human IL-2 (Gemini Bio-products), 5 μg ml<sup>-1</sup> anti-CD28-BUV737 (clone CD28.2, cat. no. 612815, BD Biosciences) and 5 μg ml<sup>-1</sup> anti-CD2 (clone RPA-2.10, cat. no. 300202, Biolegend). Cells were plated on anti-CD3- (clone SP34-2, cat. no. 551916, BD Biosciences; 1 μg per well) coated 96-well polystyrene plates and incubated at 37 °C with 5% CO<sub>2</sub> over water. Stimulated cells were with fed with fresh medium supplemented with 20 U ml<sup>-1</sup> IL-2 (final concentration) at d3 and were harvested at d6. After stimulation, cells were washed and stained with the following combination of monoclonal antibodies: anti-CD3-BUV395 (clone SP34-2, cat. no. 564117), anti-CD8-BUV496 (clone RPA-T8, cat. no. 612942), anti-Ki-67-AL700 (clone B56, cat. no. 561277), anti-CD95-PE-Cy5 (clone DX2, cat. no. 559773), anti-CCR7-PE-Cy7 (clone 3D12, cat. no. 557648) and anti-CD28-BUV737 (clone CD28.2, cat. no. 612815) (BD Biosciences); anti-CD4-PerCP-Cy5.5 (clone OKT4, cat. no. 317428), anti-PD-1-BV786 (clone EH12.2H7, cat. no. 329930) and anti-CTLA-4-PE (clone BNI3, cat. no. 369604) (Biolegend); LIVE/DEAD Fixable Near-IR Dead Cell Stain (cat. no. L34976) (Thermo Fisher Scientific). All mAbs were used at the manufacturer's recommended test volume (1:100 dilution) per 10<sup>6</sup> cells unless otherwise noted. Samples were collected on a FACSymphony system (BD Biosciences) and proliferation curves were analyzed in FlowJo (version 9.9.6, TreeStar).

**Statistical analysis.** All statistical tests were two-sided and *P* values ≤ 0.05 (95% confidence interval) were considered statistically significant for each of the specific statistical comparisons (\**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001). Data showing continuous outcomes are represented as mean ± s.e.m. All measurements were taken from distinct samples with the exception of IFN-γ ELISpot (three replicates), IPDA (eight replicates) and cell-associated SIV-DNA/RNA (12 replicates). Gaussian distribution conformity was tested using the D'Agostino–Pearson omnibus normality test. Correlations were performed using a Pearson correlation coefficient. A two-way ANOVA, or a mixed-effects model if data points were absent, was utilized to calculate significance for longitudinal, treatment-stratified datasets. All two-way ANOVAs employed row stacking for repeated

measurements, multiple comparisons with Dunnett's or Bonferroni's correction for simple effects within rows relative to control or within columns relative to treatment baseline and *P* values are reported as a multiplicity between the directions of comparison. Cross-sectional comparisons of parameters at a solitary time point were calculated using either a Mann–Whitney U test, Wilcoxon rank-sum test or a Kruskal–Wallis test with Dunn's correction for multiple comparisons. Pie chart distributions were analyzed using a permutation test (10,000 iterations) in SPICE version 6. SIV-DNA and SIV-RNA measurements were excluded for samples if fewer than 10,000 cells were sorted and values fell outside the assay limit of detection. IPDA data were excluded if they had a DNA shearing index of >25. Analyses were conducted using GraphPad Prism 8.1.2.

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

The data that support the findings of this study are available from the corresponding author on reasonable request. Sequences of gp160 *env* are available in GenBank (accession nos. MN856887–MN857133).

## References

- Del Prete, G. Q. et al. Short communication: comparative evaluation of coformulated injectable combination antiretroviral therapy regimens in simian immunodeficiency virus-infected rhesus macaques. *AIDS Res. Hum. Retroviruses* **32**, 163–168 (2016).
- Scott, M. J. et al. 'In-format' screening of a novel bispecific antibody format reveals significant potency improvements relative to unformatted molecules. *MAbs* **9**, 85–93 (2017).
- Chhabra, M. et al. Binding proteins. Patent WO/2018/083087 A2 (2018).
- Micci, L. et al. Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. *J. Clin. Invest.* **125**, 4497–4513 (2015).
- Pallikkuth, S. et al. Maintenance of intestinal Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with interleukin (IL)-21. *PLoS Pathog.* **9**, e1003471 (2013).
- Li, H. & Pauza, C. D. CD25<sup>+</sup> Bcl6<sup>low</sup> T follicular helper cells provide help to maturing B cells in germinal centers of human tonsil. *Eur. J. Immunol.* **45**, 298–308 (2015).
- Li, H. et al. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. *Proc. Natl Acad. Sci. USA* **113**, E3413–E3422 (2016).
- Amara, R. R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. *Science* **292**, 69–74 (2001).
- Hansen, S. G. et al. Addendum: immune clearance of highly pathogenic SIV infection. *Nature* **547**, 123–124 (2017).
- Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. *Cytometry A* **79**, 167–174 (2011).
- Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature* **566**, 120–125 (2019).
- Policicchio, B. B. et al. Dynamics of simian immunodeficiency virus two-long-terminal-repeat circles in the presence and absence of CD8<sup>+</sup> cells. *J. Virol.* **92**, e02100-17 (2018).
- Salantes, D. B. et al. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. *J. Clin. Invest.* **128**, 3102–3115 (2018).
- Guindon, S. et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst. Biol.* **59**, 307–321 (2010).

## Acknowledgements

We thank S. Ehnert, C. Souder and E. Strobart (Research Resources and Veterinary Medicine) at YNPRC for providing animal and veterinary care, as well as the Emory Flow Cytometry Core. We thank C. Ashman, G. Jones, L. Anderson and A. Barnard from GSK for assisting with the preparation and quality control of the therapeutic antibodies, as well as K. Fraley, A. Mayer and G. Page from GSK for measuring antibody and anti-drug antibody levels. We also thank R. Shoemaker, K. Oswald and W. Bosche at Leidos Biomedical Research for technical assistance. The SIVmac<sub>239</sub> strain used to infect the RMs was provided by K. Van Rompay of UC-Davis, anti-Gag tetramers were provided by D. Long at the NIH Tetramer Core Facility at Emory, and ART was supplied through ViiV Healthcare and GSK. This work was supported by the NIAID, NIH, under awards R01AI116379 and R21/R33AI116171 to M.P. and award UM1AI124436 (Emory CLAR). Support for this work was also provided by GlaxoSmithKline and Qura Therapeutics under subcontract 5105399 from the Collaboratory of AIDS Researchers for Eradication (CARE, 1UM1AI126619-01) to D.M., the Virology & Drug Discovery Core of Emory CFAR (P30AI050409), ORIP/OD awards P51OD011132 (YNPRC) and P51OD011092 (ONPRC), and in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. The content of this



publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.

## Author contributions

J.H. contributed to conceptualization, methodology, formal analysis, investigation, writing (original draft, review and editing) and visualization. S.G. contributed to conceptualization, formal analysis, investigation and writing the original draft. C.N.C. contributed to formal analysis, investigation and visualization. H.W., C.G., S.L.M.R., J.L.R., K.N., M.N., K.B.-S., C.K., M.P., L.M., B.C., S.J., A.S. and A.A.K. contributed to investigation. E.L. and J.S. contributed to formal analysis and investigation. S.D.F. contributed to methodology and investigation. C.S.M. contributed to conceptualization and investigation. B.J. contributed to resources. H.A.-M., J.L. and J.D.E. contributed to methodology and writing (review and editing). D.M.M. contributed to methodology, resources, writing (review and editing) and funding acquisition. G.S. contributed to writing (review and editing) and funding acquisition. K.J.B. contributed to methodology, formal analysis, and writing (review and editing). D.F. contributed to conceptualization, methodology, resources, writing (review and

editing), supervision and funding acquisition. M.P. contributed to conceptualization, methodology, resources, writing (original draft, review and editing), supervision and funding acquisition.

## Competing interests

S.G., C.G., J.S., A.S., B.J., A.A.K., H.A.-M. and D.F. are employed by and/or have financial interests in GlaxoSmithKline or ViiV Healthcare.

## Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41591-020-0782-y>.

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41591-020-0782-y>.

**Correspondence and requests for materials** should be addressed to M.P.

**Peer review information** Alison Farrell is the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).



**Extended Data Fig. 1 | Plasma viral loads during acute SIV infection and subsequent decay during ART.** Viral loads (SIV<sub>mac239</sub> RNA copies/mL) were quantified in plasma utilizing RT-qPCR and represented on a logarithmic scale. The terminal measurement (indicated in light red) for each animal indicates the start of ICB therapy (d0 p.t.). Initiation of ICB therapy was dependent on duration of undetectable viremia in plasma. Data sets are grouped based on ICB treatment as follows: **(a)** VHDUM (control; n=6), black; **(b)** anti-CTLA-4 mAb (αCTLA-4; n=6), blue; **(c)** anti-PD-1 mAb (αPD-1; n=6), pink; **(d)** anti-CTLA-4 plus anti-PD-1 mAb (combined blockade; n=7), red; and **(e)** anti-CTLA-4/PD-1 mAbdAb (BsAb; n=8), purple. Individual RMs are indicated by shape with closed data points indicating viral reactivation in plasma during subsequent ICB. The vertical dotted line indicates ART initiation (d60 p.i.) and the shaded gray area represents ongoing ART administration. The horizontal dotted line indicates the assay's limit of detection ( $\leq 60$  copies/mL) with undetectable events represented as 30 copies/mL.

**a**


Animal ID	Sex	Mamu* <sup>a</sup> A01 genotype	Age (months) <sup>a</sup> Infection	ICB	#CD4 <sup>b</sup> pre-ART	Viral load (copies/mL) <sup>c</sup> acute	pre-ART	UD Viral Load <sup>d</sup> (days)	ICB Treatment	Annotated Symbol
RGi16	M	+	31	41	748	9.7E+06	6.7E+05	195	control	○
RJd16	M	-	42	51	1474	3.1E+06	1.6E+06	195	control	□
RTw16	M	-	27	39	1753	1.2E+07	6.1E+06	138	control	△
118_14	M	-	27	38	1809	9.9E+06	7.4E+06	134	control	▽
RFu15	M	-	44	56	690	4.1E+06	1.4E+07	187	control	◇
RHj16	M	-	30	45	1292	8.9E+07	5.3E+07	152	control	⊞
RHn16	M	+	30	40	1824	6.9E+06	1.2E+06	221	αCTLA-4	○
RTj16	M	-	31	41	1390	2.0E+07	3.1E+07	198	αCTLA-4	●
RJr16	M	-	29	41	1405	1.4E+06	9.5E+06	167	αCTLA-4	□
RAq16	M	-	29	41	1600	5.5E+07	6.4E+05	262	αCTLA-4	△
138_14	M	-	25	39	269	1.3E+08	1.7E+06	182	αCTLA-4	▽
RAi16	M	-	31	46	2946	8.6E+07	4.3E+07	152	αCTLA-4	■
RWs16	M	-	29	39	530	1.2E+07	2.1E+06	190	αPD-1	○
RPo16	M	+	30	41	2099	3.7E+06	2.8E+05	198	αPD-1	●
RPN16	M	-	29	41	826	9.8E+06	5.7E+06	167	αPD-1	□
RLt16	M	-	30	42	988	4.7E+06	2.3E+07	187	αPD-1	△
RFI16	M	-	30	44	1572	1.1E+07	1.1E+07	200	αPD-1	■
82_13	M	-	42	56	N/A	1.7E+07	2.5E+07	193	αPD-1	▲
RVt16	M	-	29	39	779	3.3E+06	1.7E+06	190	combined	○
RUm16	M	-	30	41	2209	6.1E+07	4.1E+06	198	combined	●
RYi16	M	-	31	42	1764	6.0E+07	4.6E+06	138	combined	□
RVr16	M	+	29	41	1161	1.5E+07	1.4E+06	173	combined	△
RYu16	M	-	30	42	1127	4.3E+06	6.3E+06	187	combined	■
RZi16	M	-	30	45	2080	2.4E+08	8.0E+07	152	combined	▲
RHs16	M	-	28	44	555	1.4E+07	2.4E+06	152	combined	▼
RKt16	M	+	28	39	2746	1.7E+06	8.0E+02	227	BsAb	○
RZw15	M	+	43	53	439	3.9E+06	4.3E+06	162	BsAb	□
RZn16	M	-	30	41	525	1.1E+07	5.0E+06	134	BsAb	△
RUv15	M	-	43	56	1416	3.6E+06	9.9E+06	187	BsAb	●
ROp16	M	-	30	43	2571	8.8E+07	2.5E+07	191	BsAb	■
RFj16	M	-	31	45	857	1.4E+06	1.4E+07	200	BsAb	▲
RQt16	M	-	30	43	583	3.8E+06	7.5E+06	189	BsAb	▽
RKi16	M	-	32	46	3267	4.1E+06	8.4E+07	188	BsAb	▼

**b**


Treatment	abbreviation	Format	Isotype	Fc disabled <sup>e</sup>	Constant region	variable region	Bio-similar equivalent <sup>f</sup>	dose (mg/kg)	route
VHDUM	control	mAbdAb	IgG1	Yes	human	human	Palivizumab	30	i.v.
anti-PD-1	αPD-1	mAb	IgG4	Yes	rhesus	human	Nivolumab	5	i.v.
anti-CTLA-4	αCTLA-4	mAb	IgG1	No	human	human	Ipilimumab	5	i.v.
anti-CTLA-4/PD-1	BsAb	mAbdAb	IgG1	Yes	rhesus	human	Ipilimumab / proprietary	5	i.v.

**Extended Data Fig. 2 | Macaque characteristics and ICB antibodies.** <sup>a</sup>Age in months at SIV infection (d0 p.i.; post-infection) and at ICB (d0 p.t.; post-treatment). <sup>b</sup>Indicates the number of CD4<sup>+</sup> T cells per μL of PB at chronic infection prior to ART initiation (d52 p.i.) as determined by complete blood counts combined with flow cytometry. <sup>c</sup>SIV-RNA viral loads per mL of plasma was measured by quantitative RT-qPCR with a limit of detection of ≤60 copies/mL at acute (d14 p.i) and chronic infection (d52 p.i.). <sup>d</sup>Days of undetectable (UD) viral load prior to ICB treatment were calculated from the first UD observation following ART initiation and does not account for subsequent blips. <sup>e</sup>Indicates whether Fc gamma receptor has been disabled by a LAGA mutation (L235A and G237A) and is capable of antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), ect. <sup>f</sup>Indicates the pharmacological generic equivalent of the variable domain and epitope specificity.






**Extended Data Fig. 3 | Blockade pharmacokinetics and emergence of anti-drug antibodies.** (a) Plasma concentrations (ng/mL) of Co-IR blocking monoclonal antibodies (mAb) were quantified with an antibody capture assay; stratified by treatment group; and represented on a logarithmic scale. Blood was drawn immediately prior to- and 5 mins following ICB administration. (b) Using only blood drawn prior to ICB infusion, the levels of anti-drug antibodies (ECL, electrochemiluminescence) were quantified by MSD assay, which were utilized to calculate the percentage of inhibition. Vertical arrows and dotted lines represent either an ICB infusion or ART interruption, as indicated, with the gray shaded area representing ongoing ART. Individual RMs are indicated by shape with closed data points indicating animals with viral reactivation in plasma.




**Extended Data Fig. 4 | Combined blockade leads to a limited restoration of cytolytic functionality in ICR-expressing CD8<sup>+</sup> T cell subsets.** By flow cytometry, the frequencies of granzyme B<sup>+</sup> cells were determined within **(a)** CTLA-4<sup>+</sup>PD-1<sup>+</sup> and **(b)** CTLA-4<sup>+</sup>PD-1<sup>-</sup> memory CD8<sup>+</sup> T cells in LN following the fourth ICB infusion (d28 p.t.). All RMs are color-coded and grouped based on ICB therapy with population sizes as indicated for all analyses: controls (n=6), black; αCTLA-4 (n=6), blue; αPD-1 (n=6), pink; combined blockade (n=7), red; and BsAb (n=8), purple. Averaged data are presented as the mean ± s.e.m. and were analyzed with a two-sided Kruskal-Wallis test with Dunn's correction for multiple comparisons relative to controls.




Control (VHDUM)  $\alpha$ CTLA-4 (anti-CTLA-4 mAb)  $\alpha$ PD-1 (anti-PD-1 mAb) combined blockade (anti-CTLA-4 + anti-PD-1 mAb) BsAb (anti-CTLA-4/PD-1 mAb)

**Extended Data Fig. 5 | SIV-specific CD8<sup>+</sup> T cells display an exhausted phenotype that is not rescued by ICB during suppressive ART, but by viral rebound following ATI.** Within memory CD8<sup>+</sup> T cells at the on-ART, pretreatment baseline (d-29 p.t.; n=5 ICB-treated, *Mamu-A\*01*<sup>+</sup> RMs) the frequencies of exhaustion, proliferative and activation biomarkers (as indicated above) were quantified via flow cytometry in SIV-specific and non-specific subsets, as assessed by anti-Gag-CM9 staining (as indicated below) in (a) LN and (b) PBMCs. Likewise, within LN SIV-specific memory CD8<sup>+</sup> T cells the frequencies of (c) Ki-67<sup>+</sup>, (d) HLA-DR<sup>+</sup>CD38<sup>+</sup>, (e) T-bet<sup>+</sup>, and (f) Granzyme B<sup>+</sup> cells were measured at the pre-ICB baseline and following the fourth ICB infusion (d28 p.t.). Likewise, the frequencies of (g) Ki-67<sup>+</sup>, (h) HLA-DR<sup>+</sup>CD38<sup>+</sup>, (i) T-bet<sup>+</sup>, and (j) Granzyme B<sup>+</sup> cells within SIV-specific memory CD8<sup>+</sup> T cells in PBMCs were quantified at the pre-ICB baseline, following the third ICB treatment (d21 p.t.), and 15 days following ART interruption (d50 p.t.). Analyses were conducted in up to 6 *Mamu-A\*01*<sup>+</sup> RMs (g,h,i,j), of which 5 were ICB-treated (a,b,c,d,e,f). Each data point represents an individual animal, as indicated by shape, and those with ICB-related viral reactivation in plasma are represented as closed data points. Averaged data are presented as the mean  $\pm$  s.e.m. and were analyzed with (a,b) a one-way, pair-wise ANOVA using a Bonferroni correction for multiple corrections.







**Extended Data Fig. 6 | SIV-specific CD8<sup>+</sup> T cell responses are not enhanced by blockade of PD-1 and/or CTLA-4 during long-term ART.** In 5 *Mamu-A\*01*<sup>+</sup>, ICB-treated RMs, the frequency of SIV-specific cells, as determined via anti-Gag-CM9 tetramer staining with flow cytometry, were measured in (a) LN and (b) PBMC memory CD8<sup>+</sup> T cells at treatment baseline (d-29 p.t.) and following ICB (d21 or 28 p.t.). The number of interferon gamma (IFN- $\gamma$ ) spot forming units (SFU) per 10<sup>6</sup> mononuclear cells were quantified by ELISpot upon SIV-Gag stimulation in (c) PBMCs as a fold-change (d21 p.t. relative to d-29 p.t.) and (d) cross-sectionally in LN (d21 p.t.). Points represent unique animals, as indicated by shape and fill, as an average of three replicates with DMSO background subtracted. All RMs are color-coded and grouped based on ICB therapy as follows with population sizes as indicated for all ELISpot analyses: controls (n=6), black;  $\alpha$ CTLA-4 (n=6), blue;  $\alpha$ PD-1 (n=5), pink; combined blockade (n=7), red; and BsAb (n=8), purple. From *ex vivo* SIV-Gag-stimulated PBMCs with unstimulated background subtracted, the distribution of cytokine co-expression was determined via flow cytometry in memory (e) CD4<sup>+</sup> and (f) CD8<sup>+</sup> T cells before (d-29 p.t.) and during (d21 p.t.; indicated at left) ICB administration (indicated above). Rainbow-colored inner pie wedges represent each Boolean combination of cytokine co-expression (annotated at far right); whereas, the stacked, outer concentric rings overlap with pie wedges that are positive for that cytokine (indicated at middle right): IFN- $\gamma$ <sup>+</sup>, red; IL-2<sup>+</sup>, orange; TNF $\alpha$ <sup>+</sup>, green; and CD107a<sup>+</sup>, purple. Population sizes for all cytokine analyses are as follows: controls (n=6), black;  $\alpha$ CTLA-4 (n=6), blue;  $\alpha$ PD-1 (n=6), pink; combined blockade (n=7), red; and BsAb (n=8), purple. Averaged data are presented as the mean  $\pm$  s.e.m., and were analyzed with a two-sided (c,d) Mann-Whitney U test or (e,f) a Permutation test.



**Extended Data Fig. 7 | Combined blockade increases the ratio of cell-associated SIV-RNA relative to SIV-DNA content in PBMCs and limit intact provirus in LN CD4<sup>+</sup> T cells.** (a) The number of log-transformed cell-associated SIV-DNA copies per 10<sup>6</sup> PBMCs were quantified by 12 replicate reaction RT-qPCR prior to the first infusion (d0 p.t.), and 1 week following the first (d7 p.t.) and fourth infusions (d28 p.t.); from which (b) the ratio of SIV-RNA to -DNA copies was computed. All RMs are color-coded and grouped based on ICB therapy as follows with population sizes as indicated for all RT-qPCR analyses: controls (n=6), black; αCTLA-4 (n=6), blue; αPD-1 (n=6), pink; combined blockade (n=7), red; and BsAb (n=8), purple. By IPDA with ddPCR, (c) the DNA shearing index pre- and post-ICB, and (d) the fold change in intact provirus per 10<sup>6</sup> cells relative to pre-treatment baseline were quantified in LN CD4<sup>+</sup> cells. For all IPDA analyses, population sizes are as follows: control (n=3), αCTLA-4 (n=6), αPD-1 (n=5), combined blockade (n=7), and BsAb (n=7). (e) An example IPDA plot is given for the amplification of the *env* relative response element (RRE) on VIC dye against *pol* on FAM dye in relative fluorescence units (RFU). A positivity cutoff of 1250 is used for *env* and 2000 for *pol*. Sample plots shown (as indicated in red) are as follows: negative control, merged analysis from no-template control and PBMCs at pre-infection from RLt16; *env* positive control, *env* gBlock (IDT); *pol* positive control, *pol* gBlock (IDT); and IPDA (shown are LN CD4<sup>+</sup> cells at d-29 p.t. from RWs16; 1 of 58 image sets of 8 replicate reactions). Averaged data are presented as the mean ± s.e.m. Each data point represents an individual animal, as indicated by shape, and those with ICB-related viral reactivation in plasma are represented as closed data points. Data were analyzed with a two-sided (a,b) Wilcoxon matched-pairs signed rank test, (d) a Mann-Whitney U test, or (c) a two-way ANOVA with Bonferroni's correction for multiple comparisons relative to baseline and controls.




**Extended Data Fig. 8 | ICB does not differentially impact viral reservoir content between lymphoid and myeloid lineages, and vDNA content correlates with intact proviral genomes.** (a) The number of LN vRNA<sup>+</sup> cells per 10<sup>5</sup> cells were quantified by RNAscope before (d-29) and after ICB therapy (d28 p.t.). All RMs are color-coded and grouped based on ICB therapy as follows with population sizes as indicated for RNAscope analyses: controls (n=6), black;  $\alpha\text{CTLA-4}$  (n=6), blue;  $\alpha\text{PD-1}$  (n=6), pink; combined blockade (n=7), red; and BsAb (n=8), purple. In the LN B cell follicle (BCF) and T cell zone (TCZ), the number of (b) vDNA or (c) vRNA cells per 10<sup>5</sup> cells were measured based on their co-expression of CD3 (lymphoid) or CD68/CD163 (MØ; myeloid) in a subset of ICB-responsive RMs (n=19). (d) *In situ* immunofluorescence staining for CD3 (green), CD68/CD163 (blue), and DAPI (grey) combined with hybridization for SIV vDNA (red) in LN TCZ or BCF (annotated at upper right) prior to or following ICB in representative RMs (3 of 38 unique samples; up to two tissue sections were analyzed). vDNA positive cells are annotated with a white arrow and successive magnification within the indicated boxed area (white) are shown below. (e) From LN at d28 p.t., the log-transformed frequency of vDNA<sup>+</sup> cells per 10<sup>6</sup> cells were correlated against the contemporaneous frequency of log-transformed intact proviral genomes per 10<sup>6</sup> CD4<sup>+</sup> cells (n=29). Averaged data are presented as the mean  $\pm$  s.e.m. and were analyzed with (a,b,c) a two-sided Wilcoxon matched-pairs signed rank test relative to baseline or (e) a Pearson correlation coefficient.




**Extended Data Fig. 9 | Dual CTLA-4/PD-1 blockade does not control or delay viral rebound after ATI.** The delay in viral rebound by ICB was analyzed as the average number of days until detectable viral loads were observed in plasma with RT-qPCR. Plasma viral loads following ATI are shown for individual RMs by ICB: **(b)** control, **(c)**  $\alpha$ CTLA-4, **(d)**  $\alpha$ PD-1, **(e)** combined blockade, and **(f)** BsAb. *Mamu-A\*01*<sup>+</sup> RMs are shown with a bold connecting line and animals with prior ICB-related viral reactivation in plasma are represented as closed data points. The dotted horizontal line indicates the PCR assay limit of detection, with undetectable events plotted as 30 copies/mL. **(g)** Plasma viral loads following ATI were averaged by ICB and are shown with the mean as the solid line in bold and the s.e.m. represented by the color-matched shaded region. **(h)** The attenuation in set-point plasma viremia was analyzed between chronic infection (d52 p.i.) and following rebound (d170 post-ATI, p.A.). Population sizes are as follows for all viral load and rebound delay analyses: controls (n=6), black;  $\alpha$ CTLA-4 (n=6), blue;  $\alpha$ PD-1 (n=6), pink; combined blockade (n=7), red; and BsAb (n=8), purple. **(i)** By 12 replicate reaction RT-qPCR, the number of cell-associated SIV-RNA copies per  $10^6$  cells was quantified in axillary LN at necropsy: controls (n=6),  $\alpha$ CTLA-4 (n=6),  $\alpha$ PD-1 (n=5), combined blockade (n=6), and BsAb (n=7). Averaged data are presented as the mean  $\pm$  s.e.m., and were analyzed with a two-sided **(g)** two-way ANOVA with Dunnett's correction for multiple comparisons or **(a,h,i)** a Mann-Whitney U test and/or Wilcoxon ranked sign test. Color-coded statistical asterisks indicate significance between control animals and the treatment group of that color. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ .




## $\alpha$ CTLA-4




## $\alpha$ PD-1



## combined blockade



## BsAb



**Extended Data Fig. 10 | Phylogenetic trees of gp160 env sequences from plasma.** Single genome sequencing-derived gp160 env sequences from the plasma of 9 RMs are displayed in maximum-likelihood phylogenetic trees. Virus obtained from different experimental phases are as follows: blue, SIVmac<sub>239</sub> inoculum; black, chronic infection prior to ART initiation (d52 p.i.); red, during on-ART ICB-mediated reactivation (d7-28 p.t.); and green, during acute rebound post-ATI. A scale bar indicating diversity for each phylogenetic tree is indicated below and lineage determinations are annotated for RUm16 (at right). Lineages were deemed distinct if they differed at 3 or more nucleotide positions over env.